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Andrew James Schile, Ph.D.
The Rockefeller University 2009
Virtually all animal cells have the known ability to self-destruct by
undergoing apoptosis, a morphologically distinct form of programmed cell
death. The proper regulation of apoptosis is critical for both development
and tissue homeostasis, and inhibition of apoptosis contributes to the
development and progression of cancer. Inhibitor of Apoptosis Proteins
(IAPs) can bind to and inhibit caspases, the key executioners of apoptosis.
Because IAPs are frequently over-expressed in human tumors, they have
become major pharmacological targets for developing new cancer
therapeutics.

Many IAPs contain RING domains that function as E3

ubiquitin-ligases to regulate the abundance of IAPs themselves and their
binding partners by engaging the ubiquitin system.

The precise

physiological function of individual mammalian IAPs and their role as E3ubiquitin ligases in situ remain largely obscure.
Here, we investigated the function of XIAP ubiquitin-ligase activity
by deleting the RING motif via gene targeting in the mouse.

Mice

expressing XIAP ΔRING were fertile, born in expected proportions, and

were not obviously prone to disease in a pathogen-free environment.
Removing the RING finger motif stabilized XIAP protein in apoptotic
thymocytes, demonstrating that XIAP ubiquitin-ligase activity is a major
determinant of XIAP protein stability. However, consistent with earlier
reports on XIAP-null mice, we found no detectable abnormalities in
apoptosis of mutant thymocytes. On the other hand, ΔRING embryonic stem
cells and fibroblasts had elevated caspase-3 enzyme activity and impaired
ubiquitination of active caspase-3 during apoptosis.

Furthermore, XIAP

ΔRING embryonic fibroblasts were strongly sensitized to TNF-α-induced
apoptosis. Similar results were obtained with XIAP-null mice. Finally,
deletion of the RING also improved the survival of mice in the Eµ-Myc
lymphoma model.

The improved prognosis corresponded to increased

apoptosis and decreased abundance of proliferating B-cells in the bone
marrow, and a curtailed incidence of leukemia.

This demonstrates a

physiological requirement of XIAP E3 ubiquitin-ligase activity for the
inhibition of apoptosis and for tumor suppression in vivo.
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1 INTRODUCTION
1.1 Introductory comment
Cell death is a fundamental aspect of life in multicellular animals.
Genetically encoded cell death pathways appear to function as early as the
eight-cell blastocyst stage (Hardy et al., 1989), and continue during
embryonic development to mold the shape and function of organs. Cell
death functions throughout adult life as a cellular quality control mechanism
by removing superfluous or harmful cells. Cell death can be considered a
critical counterpoint to proliferation. Indeed, the two phenomena are linked
in some situations: excessive proliferation can provoke cell death (Evan et
al., 1992), while dying cells can signal their replacement by transmitting
mitogenic signals (Ryoo et al., 2004).
Virtually all animal cells have the ability to self-destruct by
undergoing apoptosis, a morphologically distinct form of programmed cell
death.

The conservation and diversification of apoptosis during the

evolution of multicellular animals point to its involvement in many vital
processes. An understanding of how cells die is important for controlling
pathologically misregulated cell death pathways. For example, it is very
likely that all tumor cells subvert cell death checkpoints in the process of
becoming malignant (Hanahan and Weinberg, 2000). Diseases as diverse as
1

stroke, neurodegeneration, and HIV infection are characterized by excessive
cell death with a strong apoptotic component as well (Thompson, 1995).
1.2 Historical perspective on programmed cell death
Nineteenth century biologists described cell deaths in developing
embryos by noting cells with atypical appearances, mostly during
metamorphosis (Clarke and Clarke, 1996). The physiological nature of cell
death was noted as early as 1842, when the German naturalist Karl Vogt
described the disappearance of the notochord during toad metamorphosis. A
relationship between death and proliferation was later described in the rat
retina (Tansley et al., 1937). Rita Levi-Montalcini and colleagues noted that
extraneous neurons are culled by cell death during development (Hamburger
and Levi-Montalcini, 1949), and that survival factors can determine which
cells live and die (Cohen and Levi-Montalcini, 1957; Levi-Montalcini and
Hamburger, 1951). Indeed, it was apparent by mid-century that death plays
important roles in animal development (Glucksmann, 1951; Saunders,
1966).

Richard Lockshin coined the phrase “programmed cell death” to

describe an active death process during metamorphosis in the tobacco worm
Manduca (Lockshin and Williams, 1965).

This observation is very

perceptive because it notes that death appears as a programmed fate. Studies
on the regressing tadpole tail helped to generalize these findings and
2

emphasize the role of macromolecular synthesis in developmental cell death
(Tata, 1966).
Apoptosis was the first form of programmed cell death to be defined
by a distinct morphology common to diverse cell types during death (Kerr et
al., 1972). Apoptosis was coined from a Greek word describing a “shedding
off” of leaves to refer to a stereotyped pattern of changes that include
membrane blebbing, nuclear condensation, cytoplasmic compaction and
DNA fragmentation (Kerr et al., 1972; Wyllie et al., 1980). The original
paper offers a wealth of prescient insights. For instance, the authors note
that recurring apoptosis reflects a conserved physiological program in
normal and diseased tissues. Apoptosis functions in the “focal elimination
of cells during normal embryonic development”, and “seems to be involved
in cell turnover in many healthy adult tissues”. Furthermore, they speculate
that apoptosis may function in “therapeutically induced tumor regression”
and “hyperplasia might sometimes result from decreased apoptosis rather
than increased mitosis.”

Their ultrastructural analyses of apoptosis in

different contexts also highlight phagocytosis, as all apoptotic cells appeared
engulfed by other cells in situ. They also postulate that apoptosis is distinct
from necrotic cell death, which occurs after insults provoke cell rupture and
inflammation (Wyllie et al., 1980).

3

Early studies on the death of developing T-cells in the thymus
implicated an intracellular nuclease in the orderly DNA fragmentation that
occurs during apoptosis (Wyllie, 1980), but the biochemical underpinnings
of apoptosis remained elusive long after the term was coined. Indeed, the
importance of cell death remained somewhat understated until the discovery
that BCL-2, a gene cloned at a chromosomal breakpoint in follicular
lymphoma, can prolong the survival of cells deprived of cytokines and
synergize with the proliferative oncogene c-Myc to immortalize B-cells
(McDonnell et al., 1989; Vaux et al., 1988). Transgenic mouse models of
cancer reveal that coexpressed BCL-2 and c-Myc provoke high-grade
lymphoma (McDonnell and Korsmeyer, 1991; Strasser et al., 1990). These
novel discoveries showed that a factor involved in cell death could serve as
an oncogene, and awakened interest in the field.
The molecular basis for apoptosis was uncovered in large part through
genetic studies in the nematode worm Caenorhabditis elegans. C. elegans is
well suited to the study of programmed cell death because each animal
generates cells during development that die invariantly (Sulston and Horvitz,
1977). Genetic screens identified ced-3 (cell death abnormal) and ced-4 as
genes required specifically for programmed cell death during development
(Ellis and Horvitz, 1986). Another gene, ced-9, was identified with an
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opposing pro-survival function: gain-of-function mutations prevent cell
death, while loss of ced-9 function kills cells that normally live (Hengartner
et al., 1992). Some cell death genes have functions conserved throughout
the evolution of multicellular animals; ced-9 is homologous to human BCL2, and BCL-2 expression rescues loss of ced-9 function (Hengartner and
Horvitz, 1994; Vaux et al., 1992).
1.3 Caspases
The key insight into the mechanism of apoptotic cell death was the
observation that ced-3 encodes a cysteine protease similar to a mammalian
protease, ICE (interleukin-1-beta converting enzyme-1) (Xue et al., 1996;
Yuan et al., 1993).

CED-3 and ICE (now caspase-1) are the founding

members of the caspase family of proteases, which are so named because
they harbor an active site containing a cysteine residue, and preferentially
cleave their substrates after aspartate residues, although glutamate is also
tolerated (Nicholson, 1999). There are least ten caspases in the human and
mouse genomes, and many of them function in apoptosis (Thornberry and
Lazebnik, 1998). Caspases are expressed as weakly active precursors that
require allosteric activation or proteolysis by other caspases before they can
cleave their substrates efficiently.
A typical caspase precursor contains an amino-terminal prodomain, a
5

large subunit, and a small subunit. Proteolysis between the domains releases
the prodomain and allows the large and small subunits to dimerize; this unit
proceeds to dimerize to form an active tetramer (Nicholson, 1999). All
caspases described to date have a dimerization interface that appears to be
critical for activity (Shi, 2002b).

Caspases recognize a tetrapeptide

sequence, P4-P3-P2-P1, and cleave after the carboxyl-terminal residue (P1).
P1 is usually Asp (though sometimes Glu), while P3 is preferentially Glu for
mammalian caspases. Different caspases have distinct but often overlapping
preferences for the P4-P3-P2-P1 sequence.
The mammalian caspases involved in apoptosis can be grouped into
two broad categories based on their domain structures. Caspases with large
prodomains (e.g., caspases-8 and -9) generally function as initiator caspases,
and depend on allosteric activation and/or association with other factors for
their activity (Shi, 2002b).

Caspases with shorter prodomains (e.g.,

caspases-3, -6. -7) appear to require cleavage, often by initiator caspases, to
become active. The large prodomains in initiator caspases contain additional
domains used for associating with activating complexes through homotypic
interactions.

Examples are the CARD (caspase recruitment domain) in

caspase-9 and its allosteric activator, Apaf-1; and DED (death effector
domain) in caspase-8 and its activator, FADD (Fas-associated death
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domain).
Caspases are only weakly active in their proenzyme forms, and
effector caspases appear to require intrachain cleavage to function.

A

framework for thinking about effector caspase activation comes from
comparisons between the structures of inactive procaspase-7 and its active
form (Chai et al., 2001b). The overall structures of inactive and active
caspase-7 are similar and both are dimers, but the peptide loops that
comprise the active site adopt a different conformation in the active caspase.
Cleavage between the small and large subunits of caspase-7 frees one of the
active site loops from a restrained covalent linkage, and allows it to adopt a
conformation that is conducive to forming an active site. This mechanism
applies to other initiator caspases, presumably (Shi, 2002b).
Activated caspases can cleave a broad range of proteins during
apoptosis; however, it is largely unclear which substrates must be cleaved
for apoptosis to proceed. The functional consequences of caspase cleavage
are known for some substrates. Nuclear lamin, for example, is cleaved by
caspases to facilitate degradation of the nucleus during apoptosis (Takahashi
et al., 1996). The fragmentation of genomic DNA that can occur during
apoptosis arises when ICAD, the inhibitor of the caspase-activated DNase
CAD, is cleaved and inactivated (Liu et al., 1997; Sakahira et al., 1998).
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Membrane blebbing and nuclear disintegration arise when caspases cleave
and activate ROCK1, a regulator of actin dynamics (Coleman et al., 2001;
Croft et al., 2005). Cleavage of β-catenin by caspases helps to promote
detachment from cellular substrata, which may aid in clearance of apoptotic
cells (Brancolini et al., 1997).

Since more than 400 human caspase

substrates have been identified to date (Luthi and Martin, 2007), it is likely
that a wide range of proteolyzed substrates contribute to apoptosis.
Some caspases have functions that appear unrelated to apoptosis.
Caspase-1, the founding member of the caspase family, processes a
precursor of the interleukin-1 cytokine involved in immunity; caspase-1
knockout mice are impaired in mounting a response to endotoxic shock (Li
et al., 1995). Caspase-8-null mice have abnormalities in heart development
that are not easily explained by defective apoptosis (Varfolomeev et al.,
1998).

A secondary role for caspases in lymphocyte development is

revealed by T-cells lacking caspase-8: mutant mice are immunodeficient,
and lymphocytes from young mice have proliferative defects (Salmena and
Hakem, 2005).

Furthermore, there are many documented cases where

caspase activity does not lead to the death of a cell. An apoptosis-like
process occurs during spermatid development in Drosophila, where caspase
activity is locally restricted to eliminate bulk cytoplasm without causing
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death (Arama et al., 2003). The differentiation pathway for macrophages
(Sordet et al., 2002) and lens development in the eye (Ishizaki et al., 1998)
require caspase activity as well.
1.4 Activation of caspases
There are two known routes to caspase activation in mammalian cells.
The mitochondrial pathway (also known as the intrinsic pathway) is
activated in response to diverse death stimuli that include genotoxic damage,
oncogene activation, and developmental cues. This route to apoptosis is sonamed because the activation steps appear to be controlled by factors
localized in or near mitochondria. An alternate pathway is activated through
death receptors and figures prominently in immunity.

Some cell types

require engagement of both pathways for efficient apoptosis.
1.4.1 Activation through mitochondrial factors
In addition to the ced-3 caspase, ced-4 is another gene required for
programmed cell death of somatic cells in C. elegans (Ellis and Horvitz,
1986). Epistasis experiments place ced-4 upstream of ced-3 as its activator
during apoptosis (Shaham and Horvitz, 1996a; Shaham and Horvitz, 1996b).
Insight into CED-4 function came after its mammalian counterpart, Apaf-1
(apoptotic protease related factor-1), was identified biochemically as an
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activator of caspase-9 which promotes caspase-3 cleavage and activation in
vitro (Li et al., 1997; Zou et al., 1997). Activation of caspase-9 by Apaf-1
requires ATP/dATP plus an additional cofactor. To date, cytochrome c is
the only known factor that can trigger the formation of an active caspase-9
holoenzyme complex, known as the apoptosome (Liu et al., 1996). The
apoptosome forms after cytochrome c binds Apaf-1, and triggers a
conformational change that permits recruitment of caspase-9 to Apaf-1 via
homotypic interactions. This functional unit oligomerizes into a wheelshaped structure with seven-fold symmetry (Acehan et al., 2002).

The

formation of an apoptosome is energy dependent and requires both an ADPATP nucleotide exchange and hydrolysis of ATP by the ATPase activity of
Apaf-1 (Riedl et al., 2005). Apaf-1 is an allosteric activator of caspase-9
that stimulates its activity toward caspase-3 by several orders of magnitude
(Rodriguez and Lazebnik, 1999).

While dimerization is necessary for

caspase-9 activity (Shiozaki et al., 2003), the intra-chain cleavage that
occurs in the apoptosome is largely dispensable for its activity. Formation
of an apoptosome appears to be a prerequisite for the recruitment and
activation of caspase-3 (Bratton et al., 2001). Although CED-4 does not
appear to require a cofactor like cytochrome c, it does oligomerize to
promote CED-3 processing and activation (Seshagiri and Miller, 1997b;
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Yang et al., 1998).
The best evidence for a linear cytochrome c-Apaf-1-caspase-9caspase-3 pathway comes from studies using mouse embryonic fibroblasts
(MEFs) from knockout animals. Cytochrome c is the only known activator
of Apaf-1 following DNA damage in MEFs. After UVC irradiation, the
apoptosome does not oligomerize in MEFs harboring a mutant cytochrome c
allele that retains respiratory functions but has a diminished capacity to bind
Apaf-1 (Hao et al., 2005). Caspase-3 cleavage is not seen and the cells are
very resistant to apoptosis.

When compared directly, this phenotype is

slightly less severe than in cells lacking Apaf-1, which suggests that other
activators of Apaf-1 may exist. Alternatively, it is possible that the mutant
cytochrome c retains some residual capacity to activate Apaf-1. Caspase-9
cleavage is almost entirely impaired in Apaf-1-null MEFs (Ho et al., 2004),
and caspase-3 cleavage is essentially absent in caspase-9-null MEFs (Kuida
et al., 1998) and ES cells (Hakem et al., 1998).
Biochemical studies and knockouts of individual components (mostly
in MEFs) order initiator and effector caspases in a cascade downstream of
mitochondria, but this may be an overly simplistic view.

Mice doubly

deficient for caspase-3 and caspase-7 display postnatal lethality and
defective heart development, while MEFs are broadly resistant to
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mitochondrial and death receptor apoptosis (Lakhani et al., 2006). This
finding argues that these caspases are required for apoptosis in MEFs and
probably other cells. Remarkably, however, many steps that are presumed
to act upstream of caspase activation are delayed in these double-knockout
MEFs.

For instance, during apoptosis in double-knockout MEFs,

mitochondrial integrity is largely maintained; BAX translocation is
diminished; and cytochrome c is released more slowly during apoptosis
(Lakhani et al., 2006). These studies argue that mitochondria may function
as amplifiers of an initial apoptotic signal in certain cell types.
There are probably other cell death pathways in thymocytes apart
from the known apoptotic programs. Thymocytes deficient for caspases-3
and -7 are resistant (though not completely) to mitochondrial apoptotic
stimuli, but die readily through receptor pathways. Thymocytes lacking the
pro-apoptotic function of cytochrome c mount normal apoptotic responses to
diverse stimuli, even though apoptosome formation does not occur; Apaf-1null thymocytes are more broadly resistant (Hao et al., 2005). Although this
cytochrome c mutant probably retains some residual capacity to activate
Apaf-1, it is very likely that thymocytes have redundant death programs that
require further elucidation. Caspase activation need not proceed directly
from initiator to effector caspases; there is evidence that caspase-6 may
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activate caspase-8, the caspase thought to be responsible for initiating death
receptor apoptosis (see below)(Murphy et al., 2004).
1.4.2 Activation through death receptors
A second pathway leading to apoptosis is triggered through cell
surface receptors that signal to activate caspases. Mouse and human cells
express a variety of receptors in the TNF-α (tumor necrosis factor α)
receptor superfamily, which includes Fas (APO-1/CD95). Death receptors
span the plasma membrane, extending an extracellular cysteine-rich motif
that binds cognate ligands and a cytoplasmic tail that signals to other factors.
The expression of receptors is often regulated; for example, resting B-cells
express low levels of the Fas receptor, but upregulate the receptor in the
presence of cytokines or endotoxins (Watanabe et al., 1995). Death ligands
such as Fas ligand (FasL) are trimers, and can be membrane bound on
signaling cells or cleaved by extracellular proteases to become soluble
factors. These ligands are usually expressed on the surface of activated Tcells and natural killer T-cells, where they have a cytotoxic function during
immune responses (Suda et al., 1993).
Fas signaling is well characterized and also considerably simpler than
the TNF-α pathway (discussed in Chapter 5).

The Fas receptor was

identified as the molecular target of an antibody (anti-APO-1) that induces
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apoptosis in malignant lymphocytes (Trauth et al., 1989). The antibody
functions as a FasL agonist that aggregates the receptor into homotrimers
(Siegel et al., 2000), and triggers assembly of a DISC (death inducing
signaling complex) on the cytosolic face of the receptor (Kischkel et al.,
1995).

The DISC forms when the receptor recruits the adaptor protein

FADD (Fas-associated death domain) through homotypic DD interactions.
FADD also contains death effector domains (DEDs) that recruit caspase-8
(also caspase-10 in human cells), also through homotypic interactions.
Caspase-8 appears to require a DISC to dimerize and activate, because the
isolated procaspase is an inactive monomer (Donepudi et al., 2003).
Procaspase-8 is cleaved after binding the DISC, possibly by auto-proteolysis
after changing conformation (Medema et al., 1997), but all of the subunits
remain associated (Lavrik et al., 2003).

The DISC appears to promote

caspase-8 dimerization and cleavage, but cleavage may be dispensible for
activity (Donepudi et al., 2003). Caspase-3 is cleaved and activated by
caspase-8 in the DISC.

Caspase-8 initiates Fas-dependent apoptosis in

MEFs; caspase-8-null cells are not killed by receptor ligation (Varfolomeev
et al., 1998). Caspase-8 activation is regulated by DISC assembly and a
competitor, c-FLIP (cellular FLICE [caspase-8]-like inhibitor protein). cFLIP exists as a short form (c-FLIPS) with two DED domains, and a long
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form (c-FLIPL) that resembles caspase-8 with two DED domains and an
non-functional active site. c-FLIPL may function as a dominant-negative
inhibitor of caspase-8 activation in the DISC, and its roles are discussed in
further detail in Chapter 5.
1.5 Regulation of cell death by anti-apoptotic proteins
Since the core apoptotic machinery appears to be universally
expressed in most cells, it is not surprising that the steps leading to caspase
activation are very tightly controlled.

One such strategy involves the

sequestration of pro-apoptotic factors in mitochondria.

For example,

cytochrome c, the only known activator of Apaf-1, is normally resident in
the intermembrane space of mitochondria. The steps leading to translocation
of cytochrome c from mitochondria to the cytosol are regulated by the BCL2 family of proteins. Initially, the anti-apoptotic function of BCL-2 was
apparent from its functional similarity to the CED-9 protein from C. elegans,
which can prevent death. Early studies showed that BCL-2 localizes to
mitochondria and prevents many manifestations of apoptosis without
promoting cell division (Hockenbery et al., 1990).
The molecular cloning of BCL-2 led to the identification of an
extended family of homologues that include anti- and pro-apoptotic
constituents.

The principal anti-apoptotic family members are BCL-XL
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(Boise et al., 1993), MCL-1 (Kozopas et al., 1993), A1 (Choi et al., 1995)
and BCL-W (Gibson et al., 1996). BAX was the first pro-apoptotic family
member and identified as a binding partner of BCL-2 (Oltvai et al., 1993),
while the related BAK was cloned by homology (Kiefer et al., 1995). Antiand pro-apoptotic BCL-2 family members are classified by their domain
organizations: factors that inhibit death seem to have four BH (BCL-2
homology) domains (BH1-4), while pro-death members have three (BH1-3).
These factors can bind each other by virtue of a BH1-3 binding pocket on
anti-apoptotic BCL-2 proteins that accommodates the BH3 domain of prodeath factors (Sattler et al., 1997).
BAX and BAK appear to require conformational changes to engage
anti-apoptotic BCL-2 proteins and promote death (Sattler et al., 1997). BAX
is present as a cytosolic or perimitochondrial monomer in healthy cells, but
changes conformation, oligomerizes and inserts into mitochondrial
membranes before apoptosis (Suzuki et al., 2000).

BAK also shifts

conformations and associates with mitochondria prior to apoptosis. The
combined activation of BAX and BAK lead to release of pro-apoptotic
factors like cytochrome c from mitochondria into the cytosol (Wei et al.,
2001). How this happens is unknown, but recombinant BAX and BAK are
capable of forming pores in isolated vesicles (Korsmeyer et al., 2000).
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While mice deficient for either BAX or BAK are viable, the compound
knockout results in neonatal lethality with a very high penetrance (Lindsten
et al., 2000). This is probably because BAX and BAK double knockout cells
are virtually resistant to apoptotic stimuli that involve mitochondrial factors
(Wei et al., 2001).
Although it is still unclear how BAX and BAK are activated, their
pro-death functions appear to depend on factors from a third class of BCL-2
family members that harbor only the third BH domain (“BH3-only”). This
family has grown to include a large number of BH3-only proteins since the
identification of the founding member, BID (Wang et al., 1996). The wide
variety of regulatory steps that control individual BH3-only proteins stresses
their roles in activating apoptosis in response to distinct stimuli.

For

example, the BH3-only genes PUMA (Nakano and Vousden, 2001) and
NOXA (Oda et al., 2000) are upregulated by p53 following genotoxic stress;
PUMA is the key transducer of apoptotic signaling to BAX and BAK after
DNA damage in many cell types (Villunger et al., 2003). BIM is the key
mediator of apoptosis triggered by cytokine withdrawal, and has a role in
promoting the death of autoreactive lymphocytes during development
(Bouillet et al., 1999). Additionally, the BH3-only protein BMF is poised to
trigger apoptosis when cells detach from extracellular substrata by its
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association with myosin bundles (Puthalakath et al., 2001). The BH3-only
protein BID is required for death receptor apoptosis in cells like hepatocytes,
where it amplifies the apoptotic signal through the mitochondrial pathway
(Yin et al., 1999).

BID is cleaved by caspase-8 during death receptor

signaling; truncated BID inserts into mitochondrial membranes to promote
BAX and BAK oligomerization and mitochondrial relocalization, which in
turn promotes cytochrome c release (Desagher et al., 1999).
Individual BH3-only proteins bind distinct but overlapping subsets of
pro- and anti-apoptotic BCL-2 proteins (Chen et al., 2005). This led to a
hypothesis that certain BH3-only proteins like BIM and BID function as
“activators” that directly activate BAX and BAK, while others like BAD and
NOXA act as “sensitizers” by displacing anti-apoptotic BCL-2 factors from
the activators (Letai et al., 2002). An alternative hypothesis stresses the
point that BH3-only factors can activate apoptosis indirectly by inhibiting
the anti-apoptotic BCL-2 proteins (Willis et al., 2005).

The proposed

mechanisms are not necessarily exclusive, and the interactions that lead to
mitochondrial membrane permeabilization and cytochrome c release clearly
require further research.
The central logic behind the apoptotic pathway appears throughout
multicellular animals. C. elegans relies on a streamlined version of the
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pathway described above. The C. elegans genome harbors an anti-apoptotic
BCL-2 gene, ced-9 (Metzstein et al., 1998), and at least two BH3-only
genes, egl-1 and ced-13 (Schumacher et al., 2005).

ced-13 is

transcriptionally upregulated in the germline by a p53 homologue, while egl1 is more broadly utilized in the soma; both act pro-apoptotically by
preventing CED-9 from inhibiting CED-4 (Schumacher et al., 2005; Yan et
al., 2005).
1.6 IAPs: negative regulators of caspases
In most cells, caspases are subject to at least two forms of negative
control. The activation steps are regulated in the mitochondrial and receptor
routes to apoptosis: BCL-2 proteins determine whether mitochondrial factors
like cytochrome C translocate to the cytosol to activate caspases, while the
death receptor pathway requires ligands to activate initiator caspases.
Furthermore, caspases are subject to negative regulation by inhibitors. One
important group of negative caspase regulators includes the Inhibitor of
Apoptosis Proteins (IAPs) (Miller, 1999). The first IAPs were identified in a
genetic complementation screen for genes in the baculovirus genome that
could substitute for loss of p35, then the only known inhibitor of cell death
in virally infected insect cells (Birnbaum et al., 1994; Crook et al., 1993).
This effort led to the identification of iap in the genome of Autographa
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californica nuclear polyhedrosis virus, as well as homologues like Op-iap
from Orgyia pseudotsugata virus (Clem and Miller, 1994; Crook et al.,
1993). Baculovirus IAPs are characterized by a unique zinc finger motif of
about 80 amino acids, later known as the BIR (for baculovirus IAP
repeat)(Crook et al., 1993). Insights into baculoviral IAP function came
from the observation that Op-IAP inhibits the processing and activation of
an insect effector caspase during viral infection (Seshagiri and Miller,
1997a). Subsequent work showed that BIR domains are principally involved
in binding to and inhibiting caspases (Takahashi et al., 1998).
The discovery of related genes in insect and mammalian genomes
suggested that IAPs might be part of a larger regulatory scheme (Salvesen
and Duckett, 2002; Vaux and Silke, 2005). The cellular IAPs (cIAPs) 1 and
2 were identified biochemically in human cells as binding partners of the
TRAF2 protein in TNF-α apoptosis (see introduction to Chapter 5)(Rothe et
al., 1995), while the X-chromosome-linked IAP (XIAP) was identified by
homology to other IAPs (Duckett et al., 1996). In mammals, the other BIRcontaining proteins are ML-IAP (melanoma IAP) (Vucic et al., 2000),
Bruce/apollon (Chen et al., 1999), Survivin (Ambrosini et al., 1997), and a
testis-specific IAP (ts-IAP) present in great apes (Richter et al., 2001). All
of these IAPs bear at least one BIR, while cIAP1, cIAP2, XIAP ts-IAP, and
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ML-IAP harbor RING domains.

cIAP1 and cIAP2 also have a CARD

domain. The Drosophila genome harbors two IAPs, DIAP1 and DIAP2,
with two BIR domains and a RING motif. The C. elegans genome has a
Survivin-like gene, but Survivin probably does not function in cell death
(Lens et al., 2006). The lack of any apparent IAPs in C. elegans might
reflect the need for expanded control over caspases in more complex or
longer-lived organisms.
1.6.1 Inhibition of caspases by direct binding
The discovery that XIAP can bind and inhibit caspases with BIR
domains partly explains why IAP expression prevents death (Deveraux et
al., 1997; Takahashi et al., 1998). XIAP is the most studied mammalian
IAP, probably because it is the best inhibitor of caspases in vitro (Eckelman
and Salvesen, 2006). XIAP can directly bind and inhibit caspases through
BIR domains present in triplicate in the amino-terminal half of the protein.
Deletion mapping and structural studies reveal how XIAP can inhibit
different caspases. A peptide sequence that includes the second BIR domain
binds to and inhibits active caspases-3 and -7 by a common mechanism
(Chai et al., 2001a; Riedl et al., 2001; Sun et al., 1999). The initial structural
studies revealed that a short peptide sequence on the immediate aminoterminal side of BIR2 is necessary for caspase inhibition. This section of the
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linker between BIR1 and BIR2 forms a hydrophobic binding pocket that
spans the caspase catalytic groove in the opposite orientation from caspase
substrates.

This interaction precludes access to the caspase active site.

Subsequent studies have shown that the BIR2 makes additional contacts
with caspases-3 and -7 that stabilize the interactions (Scott et al., 2005).
Two closely related IAPs, cIAP1 and cIAP2, can bind caspases-3 and -7 but
inhibit their enzymatic activity very poorly in vitro (Eckelman and Salvesen,
2006). The differences appear to lie in the linker region between BIR1 and
BIR2, because replacing the cIAP1 or cIAP2 linker with the XIAP linker
increases caspase inhibition.
XIAP inhibits caspase-9 by a different mechanism altogether
(Shiozaki et al., 2003). XIAP associates with the apoptosome (Bratton et al.,
2001), where the XIAP BIR3 makes a large continuous contact with a
caspase-9 monomer. This interaction simultaneously maintains the caspase
as an inactive monomer and precludes the active site from adopting a
productive conformation.

Sequestering caspase-9 as a monomer is

especially inhibitory because caspases must dimerize to be active (Shi,
2002b).

XIAP BIR3 forms a hydrophobic binding pocket that makes

additional contacts with the amino-terminal tetrapeptide of the caspase-9
small subunit known as the IAP binding motif (IBM). Although cIAP1 and
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cIAP2 also bind the caspase-9 IBM through a similar pocket in BIR3, they
lack a suitable interface for holding caspase-9 in a monomeric state. This
observation probably explains why these IAPs are poor inhibitors of
caspase-9 (Eckelman and Salvesen, 2006).
1.6.2 Inhibition of caspases through ubiquitination
In addition to BIR domains that can bind and inhibit caspases, many
IAPs also contain a RING (really interesting new gene) domain that bestows
ubiquitin-ligase functions. RING domains are found in diverse proteins and
impart substrate specificity to the ubiquitin system (Joazeiro and Weissman,
2000).

The ubiquitin system is the principal mechanism for actively

regulating the abundance of proteins in eukaryotic cells (Glickman and
Ciechanover, 2002).

Ubiquitin-ligases can target proteins for degradation

by assembling ubiquitin polymers on specific substrates.

Polyubiquitin

chains are assembled through the sequential activity of three highly
conserved classes of enzymes. In the first step, the E1 ubiquitin-activating
enzyme forms a high energy intermediate between an active site cysteine
side chain and a ubiquitin monomer. This step requires energy in the form
of ATP. The activated ubiquitin is then transferred to an active site cysteine
in the E2 ubiquitin-conjugating enzyme.

The E3 ubiquitin-ligase

simultaneously binds its cognate E2 and the substrate to be ubiquitinated,
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and juxtaposes the two to promote ubiquitin transfer between the E2 and an
internal lysine on the substrate.

In the case of RING E3s, the ubiquitin is

transferred without forming a RING-ubiquitin intermediate, as there are no
catalytic residues. The RING may serve as an allosteric activator of the E2,
or perhaps by forming a scaffold to structurally coordinate ubiquitin transfer
(Glickman and Ciechanover, 2002). Generally, eukaryotic genomes harbor
two E1 enzymes and several hundred E2s; mammalian genomes contain
possibly as many as 1000 RING E3s. This observation highlights the central
role that ubiquitination plays in regulating diverse cellular processes.
The way in which a RING ubiquitinates its substrate influences the
outcome of ubiquitination (Hochstrasser, 2006). The majority of RINGs
studied so far appear to form a polyubiquitin chain on their substrates
through iterative addition of ubiquitins through Lys48 linkages (Pickart and
Eddins, 2004). A typical polyubiquitin chain contains more than a dozen
ubiquitin moieties, but extension of a Lys48 ubiquitin chain to four or more
subunits appears to constitute a minimal recognition sequence for the
proteasome, the elaborate protease complex that proteolyses ubiquitinated
substrates (Thrower et al., 2000).

Alternatively, a RING can mono-

ubiquitinate a substrate, or form polyubiquitin linkages with different
topologies that may not necessarily lead to degradation by the proteasome

24

(Vaux and Silke, 2005).

An example of this is the Lys63-linked

polyubiquitin chain assembled on RIP1 and TRAF2 to activate the canonical
NF-κB pathway (discussed below in the introduction to Chapter 5).
Additionally, ubiquitin was discovered as a covalent histone modification
(Goldknopf and Busch, 1975) that does not promote degradation by the
proteasome.

Many aspects of the ubiquitin system are mysterious. For

instance, it is not clear exactly how a RING E3 can activate its cognate E2 to
promote ubiquitin transfer because the E2 does not appear to change
conformation after binding an E3 (Hochstrasser, 2006).
IAP RINGs have been studied thoroughly in Drosophila, where
DIAP1 functions as an E3-ubiquitin ligase for regulating cell death and
survival.

This includes targeting the caspase-9 ortholog DRONC for

degradation by the proteasome in living cells, and promoting selfconjugation and DIAP1 degradation under apoptotic conditions (Ryoo et al.,
2002; Ryoo et al., 2004; Wilson et al., 2002).

Loss of DIAP1 RING

function leads to late embryonic lethality accompanied by massive levels of
apoptosis, which closely mimics a complete loss of DIAP1 function (Goyal
et al., 2000; Lisi et al., 2000).

Point mutations that inactivate RING

ubiquitin-ligase function do not preclude DIAP1 from binding the initiator
caspase DRONC, but they do prevent polyubiquitination of DRONC
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(Wilson et al., 2002). In principal, loss of an anti-apoptotic function of the
DIAP1 RING (e.g., polyubiquitinating DRONC) could be mitigated by the
concurrent loss of a pro-apoptotic function (e.g., promoting self-conjugation
and degradation).

In the absence of DIAP1 RING function, however,

DIAP1 is stabilized and its protein levels are increased, but the net outcome
for most cells is still excessive cell death due to highly elevated DRONC
levels (Ryoo et al., 2004).
Among mouse IAPs, XIAP, cIAP1, cIAP2 and ML-IAP all have
RING domains, but their functions in vivo are largely unknown (Vaux and
Silke, 2005).

The RING domains of XIAP and cIAP1 regulate the

abundance of these proteins during apoptosis in primary mouse thymocytes
(Yang et al., 2000). XIAP and cIAP1 can both self-conjugate polyubiquitin
chains in vitro. This is the first function assigned to IAP RINGs, and it is
hypothesized

to

underlie

the

death

of thymocytes

because

IAP

downregulation occurs before many manifestations of apoptosis (Yang and
Li, 2000).

Consistent with this notion, a RING-deleted XIAP is stably

expressed in a mouse T-cell hybridoma and imparts resistance to diverse
death stimuli (Yang et al., 2000). There is evidence that the XIAP RING
can regulate the abundance of active caspase-3 subunits during apoptosis
(Suzuki et al., 2001), in a manner reminiscent of how DIAP1 RING
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regulates DRONC (Wilson et al., 2002). These experiments are difficult to
interpret because they involve ectopic expression of active-site mutants of
caspase-3, and XIAP binds caspase-3 at its active site (Riedl et al., 2001).
There are also in vitro and overexpression data implicating XIAP RING in
regulating the abundance of the large subunit of active caspase-9 (Morizane
et al., 2005) and active caspase-7 (Creagh et al., 2004). These experiments
are also difficult to interpret because it is unclear how much of the observed
changes are owing to overexpression artifacts.
1.7 IAP antagonists
Genetic studies in Drosophila identified a novel class of IAP
antagonists that derepress caspases, at least in part by competitively
displacing them from IAPs.

The three founding members of the IAP

antagonist family, Reaper, Hid (head involution defective) and Grim, were
discovered as three tightly linked loci in a genomic region required for
initiating all cell death during Drosophila development (White et al., 1994).
Reaper, Hid and Grim function as integrators that relay diverse pro-apoptotic
stimuli, ranging from developmental cues to genotoxic damage, to trigger
cell death. All three proteins share a structurally conserved N-terminal IAPbinding-motif (IBM) that can bind BIR domains (Shi, 2002a). The IBM
appears to be the basis for caspase derepression, since IAP antagonists can
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liberate caspases from IAPs by binding BIR domains more tightly (Shi,
2002b; Srinivasula et al., 2001).
IAP antagonists appear in a central position to dictate the outcome of
DIAP1 E3 activity. Expression of Reaper depletes DIAP1 through RINGdependent autoubiquitination, leading to apoptosis in the wing imaginal disc
and other tissues (Ryoo et al., 2002). Furthermore, Ubcd1, which encodes a
cognate E2 for DIAP1 RING, genetically interacts with DIAP1 and is
required for Reaper-dependent apoptosis (Ryoo et al., 2002). Structural
studies offer some insights into how IAP antagonists might regulate DIAP1
RING ubiquitination of caspases (Chai et al., 2003). DRONC binds DIAP1
BIR2 using a peptide sequence that maps between the prodomain and the
large subunit, but is distinct from the typical IBM interface. The DRONC
and Reaper/Hid/Grim binding sites overlap, however, which allows IAP
antagonists to compete for BIR2 using tighter binding affinities (Wu et al.,
2001). In this manner, IAP antagonists liberate DRONC and prevent DIAP1
RING from ubiquitinating it. Although DIAP1 has intrinsic tendency to
autoubiquitinate in vitro, it is still unclear how IAP antagonists stimulate this
phenomenon during apoptosis. Perhaps DIAP1 has no other local substrate
when bound to a small IAP antagonist like Reaper (65 amino acids).
Mammalian genomes harbor many genes that bear superficial
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similarities to fruit fly IAP antagonists.

Smac (second mitochondrial

activator of apoptosis) was identified biochemically as a factor present in the
detergent-soluble membrane fraction that promotes caspase-3 activation in
cellular extracts (Du et al., 2000); the same protein was identified as a
binding partner of XIAP, and named DIABLO (direct IAP binding protein
with low pI) by a second group (Verhagen et al., 2000).

Smac is a

homodimer that localizes to the mitochondria in healthy cells and egresses to
the cytosol during apoptosis, where it antagonizes IAPs and promotes
caspase activation. The amino-terminal tetrapeptide motif (AVPI) of mature
Smac shares sequence similarity to the amino-termini of fruit fly IAP
antagonists (Reaper: AVAF; Hid: AVPR; Grim: AIAY). It is also very
similar to the IBM of the caspase-9 small subunit (human: ATPF; mouse:
AVPY), which suggests a mechanism for how Smac can competitively
liberate caspase-9 from XIAP in the apoptosome (Srinivasula et al., 2001).
Indeed, the crystal structure of a XIAP/Smac complex confirms that Smac
binds the same hydrophobic IBM-binding grooves in BIR2 (Chai et al.,
2000) and BIR3 (Liu et al., 2000; Wu et al., 2000) where caspases also bind
(Scott et al., 2005; Shiozaki et al., 2003). While monomeric Smac suffices
to liberate caspase-9 from BIR3, dimeric Smac appears to be required to
derepress effector caspases probably because these caspases make additional
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contacts with the BIR2 linker in addition to the BIR2 IBM pocket (Chai et
al., 2000; Gao et al., 2007).

IBM binding grooves appear to have a

conserved function throughout evolution, as they are found in DIAP1 as well
(Wu et al., 2001). The IBMs of Grim and Hid bind DIAP1 BIR2 (the
counterpart to XIAP BIR3) similarly to how Smac binds XIAP (Chai et al.,
2003). Another mammalian IAP binding protein, Omi, is a serine protease
known to compete with XIAP for binding to caspases using similar
principles (Vaux and Silke, 2003). ARTS (apoptosis related protein in TGFβ signaling pathway) is another IAP antagonist that can target XIAP
(Gottfried et al., 2004; Larisch et al., 2000). Recently, a panel of other IAP
antagonists have been identified as XIAP binding partners, and all appear to
have IBM motifs (Verhagen et al., 2007). The functions of these proteins
during apoptosis are largely unknown.
IAP antagonists function pro-apoptotically and their activity must be
regulated to prevent spurious induction of cell death programs. Reaper, for
example, is probably only present in cells that are doomed to die (Steller et
al., 1994). Transcriptional activation of the Reaper locus appears to underlie
many forms of apoptosis in Drosophila, ranging from developmental cell
death (Jiang et al., 2000; Lohmann et al., 2002) to apoptosis following
genotoxic damage (Brodsky et al., 2000; Nordstrom et al., 1996). Hid is
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broadly expressed in most Drosophila cells, including viable cells, but is
negatively regulated by survival signaling through the Ras pathway at the
transcriptional (Kurada and White, 1998) and post-translational levels
(Bergmann et al., 1998). Remarkably, all of the known mammalian IAP
antagonists seem to localize to mitochondria and are released to the cytosol
during apoptosis (Vaux and Silke, 2003). This finding emphasizes the logic
behind

sequestering

pro-apoptotic

factors

in

distinct

subcellular

compartments to discourage accidental cell death.
It is unclear if IAP antagonists play a central role in regulating IAP
abundance in mammals as they do in Drosophila. Ectopic expression and in
vitro experiments provide all of evidence that IAP antagonists can regulate
IAP abundance. Ectopic expression of active (e.g., with a cleaved aminoterminal mitochondrial localization sequence) Smac efficiently depletes
cIAP1 and cIAP2, but not XIAP, in HeLa cells. Expression of active Smac
may actually antagonize XIAP E3 activity (Creagh et al., 2004; Silke et al.,
2004). Similarly, small-molecule IAP antagonists deplete cIAP1 and cIAP2
efficiently but leave XIAP expression relatively unchanged (Varfolomeev et
al., 2007; Vince et al., 2007). ARTS might function similarly as fruit fly
IAP antagonists, because expression of ARTS can deplete XIAP from cells
(Gottfried et al., 2004).

31

Drosophila IAP antagonists have apoptotic functions in mammalian
cells. Expression of Grim in human 293T cells depletes XIAP efficiently
but does not induce apoptosis (Silke et al., 2004); however, expressing Hid
depletes XIAP (A. Kelkar, personal communication) and correlates with
apoptotic cell death that can be inhibited by IAPs in Hela cells (Haining et
al., 1999). Reaper also functions in mammalian cells by stimulating XIAP
autoubiquitination (Holley et al., 2002).

Some of the mammalian IAP

antagonists probably do function like fruit fly antagonists because the
functions of Reaper, Hid and Grim are conserved. It is clear that the biology
of IAP antagonists requires more investigation.
1.8 Mouse models of IAP function
Flies lacking DIAP1 function die as embryos because of ubiquitous
apoptosis (Goyal et al., 2000; Lisi et al., 2000). Surprisingly, however,
individual genetic deletions of XIAP (Harlin et al., 2001; Olayioye et al.,
2005), cIAP1 (Conze et al., 2005), or cIAP2 (Conte et al., 2006) by
homologous recombination result in an essentially normal mouse on
commonly used genetic backgrounds (C57BL/6 or 129/Ola).

XIAP-null

females show delayed lobuloalveolar development accompanied by reduced
milk protein synthesis, but this effect does not seem related to apoptosis
(Olayioye et al., 2005). The roles of individual IAPs in regulating apoptosis
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during development may be masked by a combination of functional
redundancy and compensatory upregulation. For example, there is evidence
for IAP cross-regulation and possible redundancy in cells from the cIAP1null mouse (Conze et al., 2005). cIAP2 levels increase post-translationally
in cIAP1-null cells because cIAP1 negatively regulates the abundance of
cIAP2 through ubiquitination and proteasomal degradation.

XIAP

expression is unaltered in cells from cIAP1-null mice, however, and its
expression levels have yet to be addressed in cIAP2-null cells. cIAP2-null
mice are resistant to endotoxic shock by bacterial lipopolysaccharide
administration (Conte et al., 2006).

This phenotype may arise because

macrophages from cIAP2-null mice are sensitized to Fas apoptosis following
endotoxic shock; cIAP2 expression increases by about 30-fold in endotoxin
treated WT cells, which may explain why these cells normally survive.
The role of functional redundancy could be addressed by generating
compound mutant mice by interbreeding existing knockouts. The relatively
unstudied members of the IAP family should be included in this effort. For
example, ML-IAP harbors a RING ubiquitin-ligase domain and a BIR
domain that binds caspases weakly but Smac strongly (Vucic et al., 2002).
To our knowledge, ML-IAP has not been knocked out in mice. Another
IAP, Bruce/Apollon, is unique not only for its size (528 kDa) but also
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because it harbors an E2 ubiquitin-conjugating domain that can participate in
polyubiquitinating Smac and caspase-9 when all are ectopically expressed
(Hao et al., 2004). The functions of Bruce in vivo are hard to discern
because the three knockout mice generated so far (two by gene targeting and
one by gene trapping) yield conflicting results. All three Bruce-null mice
are lethal in utero, though not at the same developmental stages (Hao et al.,
2004; Lotz et al., 2004; Ren et al., 2005). One group (Ren et al., 2005)
noted increased apoptosis in situ that associated with lethality in their genetrapped knockout, while the others (Hao et al., 2004; Lotz et al., 2004) did
not observe appreciable differences in death in gene-targeted embryos. Two
groups (Hao et al., 2004; Ren et al., 2005) describe increased sensitivity to
apoptotic stimuli in embryonic fibroblasts, while a third group reports no
difference (Lotz et al., 2004).

Bruce has other functions unrelated to

apoptosis (Pohl and Jentsch, 2008), which is not surprising given the size of
the protein. It is intriguing that the mutant with the most severe apoptosis
phenotype (Ren et al., 2005) retains the BIR but not the E2 domain, while
the other two mice lacked the entire gene. Studies on the fly homologue,
dBruce, highlight the central importance of E2 domain in enhancing Reaper
and Grim-dependent death (Vernooy et al., 2002). Perhaps the presence of
the BIR is sufficient to subvert any compensatory mechanisms in place in
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mouse cells. More work is clearly needed to address the role of Bruce and
ML-IAP in relation to other mammalian IAPs.
XIAP-null thymocytes, splenocytes and embryonic fibroblasts die
normally in response to many different apoptotic stimuli; however, postmitotic cells cultured from XIAP-null mice show some apoptosis phenotypes
that offer some deep insights into tissue-specific regulation by XIAP.
Sympathetic neurons (Potts et al., 2003) and cardiomyocytes (Potts et al.,
2005) from XIAP-null mice rapidly die by apoptosis after microinjection of
cytochrome c, while cells from WT mice are completely insensitive. Dermal
fibroblasts from XIAP-null and WT mice are equally sensitive to cytochrome
c injection, however. XIAP inhibition is also necessary for apoptosis to
occur following nerve growth factor withdrawal in cultured sympathetic
neurons (Potts et al., 2003). Similar observations are seen in neuronally
differentiated PC12 pheochromocytoma cells, which require inhibition of
XIAP to die (Perrelet et al., 2002; Vyas et al., 2004). It is unknown if XIAPnull mice are prone to neurodegenerative diseases.
These observations show that XIAP is a non-redundant regulator of
apoptosis in certain post-mitotic cells, some of which (e.g., neurons) can
persist throughout life. Intriguingly, the expression levels of Apaf-1 are
inversely related to how well XIAP can inhibit caspases and apoptosis after
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cytochrome c release (Potts et al., 2005). Downregulation of Apaf-1 seems
to be an effective strategy employed by post-mitotic cells to ensure that
XIAP remains an effective inhibitor of caspases.

Proliferative cells

represent a greater danger to the organism as a whole; perhaps it is not
surprising that there are alternate routes to apoptotic and non-apoptotic death
that may be independent of IAPs.
The IAP antagonists Smac and Omi have been disrupted individually
and together in the mouse (Martins et al., 2004; Okada et al., 2002). Smacnull mice are viable and fertile. Caspase-3 activation is impaired in vitro in
Smac-null fibroblast lysates; however, apoptosis occurs normally in cultured
primary and transformed fibroblasts, embryonic stem cells, hepatocytes and
thymocytes (Okada et al., 2002). A role for Smac in apoptosis has emerged
by comparing apoptosis in embryonic myoblasts and fibroblasts from Smacand Apaf-deficient mice (Ho et al., 2007). XIAP is expressed at lower levels
in myoblasts than fibroblasts.

Release of Smac into the cytosol during

mitochondria-dependent apoptosis is sufficient to neutralize XIAP in
myoblasts, and caspase activation and apoptosis occur even the absence of
Apaf-1. Simultaneous deletion of Smac and Apaf-1 is necessary to block
apoptosis in myoblasts. This type of regulation does not occur in fibroblasts
because of the elevated level of XIAP; however, neutralization of XIAP by

36

small-molecule inhibitors allows apoptosis to occur in the absence of Apaf-1.
These experiments reveal two independent pathways that can activate
caspases and apoptosis in mammalian cells: one depends on Apaf-1, and the
other is regulated by XIAP and IAP antagonists. Similar logic underlies
caspase activation in Drosophila (Zhou et al., 1999).
The Omi knockout mouse suffers from a neurodegenerative disorder
(Martins et al., 2004); however, this phenotype is owing to loss of Omi
serine protease activity, rather than loss of IAP inhibitory function (Jones et
al., 2003). Compound deletion of Smac and Omi does not exacerbate this
phenotype.

A physiological role of these proteins for regulating IAPs

remains to be established, but this is possibly masked due to functional
redundancy and the presence of additional IAP-antagonists. Indeed, there
are far more potential IAP antagonists than IAPs in mammalian genomes
(Vaux and Silke, 2003; Verhagen et al., 2007). Loss of Sept4, the locus
encoding ARTS, results in male sterility accompanied by increases in XIAP
expression in the testis (Kissel et al., 2005). ARTS can regulate XIAP
expression by promoting auto-ubiquitination and degradation by the
proteasome (Gottfried et al., 2004). Furthermore, loss of ARTS worsens
prognosis on the Eµ-Myc lymphoma background corresponding to decreased
apoptosis in vivo (M. García-Fernández and H. Steller, unpublished data).
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1.9 Roles of IAPs outside of apoptosis
Many IAPs may be multifunctional proteins with roles distinct from
regulating caspases and apoptosis. Overexpression of IAPs can activate
diverse signaling pathways, including JNK, TGF-β and NF-κB (Lewis et al.,
2004), but it is unclear if these are physiological observations. XIAP and
cIAP1 are reportedly positive regulators of the NF-κB pathway downstream
of the TNF-α cytokine, as cells with silenced expression of XIAP (Gaither et
al., 2007) or cIAP1 (Tang et al., 2003) cells show signs of reduced NF-κB
activity.

Primary cIAP1-null fibroblasts still activate NF-κB normally

(Conze et al., 2005; Vince et al., 2007), so the observed effects may be cell
type specific or possibly overexpression artifacts.

XIAP may have a

function in the bone morphogenetic protein (BMP) signaling pathway
involved in developmental patterning. The carboxyl-terminus of XIAP can
bind BMP receptors, and BIR1 can bind the adaptor protein TAB1
(Yamaguchi et al., 1999). TAB1 in turn recruits a member of the mitogen
activated protein kinase (MAPK) kinase kinase TAK1, which in turn
activates NF-κB signaling (Lu et al., 2007). The physiological significance
of this interaction is unclear because the conclusions rely from
overexpression experiments, and this has yet to be validated by genetic or
other approaches.
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1.10 IAPs in cancer and other diseases
Mammalian IAPs, and XIAP in particular, can inhibit apoptosis
triggered through diverse stimuli when overexpressed (LaCasse et al., 1998).
Elevated IAP expression is documented in human tumors (Tamm et al.,
2000; Tamm et al., 2004), and correlates with high levels of active caspases
(Yang et al., 2003). There are few published correlation studies, however,
and the prognostic significance of XIAP overexpression is unclear (Fulda,
2007). The tightly linked cIAP1 and cIAP2 loci are frequently amplified in
lung cancer (Dai et al., 2003), while cIAP1 is amplified specifically in
cervical cancer (Imoto et al., 2002) and correlates with resistance to
radiotherapy. cIAP1 is also amplified in human hepatocellular carcinoma
and experimentally induced liver cancer in mice (Zender et al., 2006).
Indeed, cIAP1 overexpression has a pathogenic role in hepatocellular
carcinoma (Zender et al., 2006). A chromosomal translocation common to
extranodal marginal zone mucosa-associated lymphoid tissue (MALT) Bcell lymphomas juxtaposes the cIAP2 BIR domains with a caspase-like gene,
MALT1 (Baens et al., 2000; Uren et al., 2000). The chimeric cIAP2/MALT
protein displays enhanced NF-κB survival signaling (Zhou et al., 2005) and
promotes tumorigenesis in a transgenic mouse model (A. Stoffel,
unpublished data).
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With the exception of cIAP1 in liver cancer, the associations between
IAP overexpression and tumorigenesis remain correlative. In spite of this,
diverse strategies to inhibit IAPs have pro-apoptotic effects in many
contexts. Downregulation of XIAP through antisense or interfering RNAs,
or therapeutic peptides derived from IAP antagonists, sensitizes tumor cells
to apoptosis and offers some promise for future therapy (Hunter et al., 2007).
Smac-derived peptides (Fulda et al., 2002) or small-molecules (Petersen et
al., 2007), or XIAP antisense treatments (Cummings et al., 2006), synergize
with apoptotic stimuli to reduce tumor xenografts in mice. Small-molecule
IAP antagonists have been developed by many groups, and they offer
promising therapeutic advantages (Sun et al., 2006; Vucic and Fairbrother,
2007). Some of these antagonists have entered Phase I clinical trials for
treatment in different malignancies.
IAPs may have roles in other disease contexts as well.

Many

neurodegenerative diseases have a strong apoptotic component, and blocking
apoptosis could have therapeutic benefits (Mattson, 2000). XIAP gain-offunction models (e.g., overexpression) have been used to demonstrate
involvement of IAPs in neurodegeneration.

Overexpression of XIAP

protects motor neurons in an experimental model of sciatic denervation
(Perrelet et al., 2002). Transgenic expression of XIAP in neurons using the

40

neuron-specific enolase promoter (nse-XIAP) improves prognosis in a mouse
model of Parkinson’s disease (Crocker et al., 2003). Overexpression of
XIAP also improves the survival of human pancreatic islets after
transplantation in a mouse model of diabetes treatment (Emamaullee et al.,
2005). Thus, IAP function may be modulated to either enhance apoptosis in
diseases like cancer that display resistance to death, or reduce apoptosis in
degenerative diseases.
1.11 Concluding remarks
Despite huge gains in our understanding of proteins involved in
apoptosis, many aspects of cell death remain obscure. This is true both for
particular aspects of cell death (e.g., regulation of IAPs), but also in broader
contexts. For example, thymocytes lacking Apaf-1 (Yoshida et al., 1998) or
caspase-9 (Hakem et al., 1998) are broadly resistance to apoptotic stimuli in
culture, but thymus development is still largely normal. On a mixed genetic
background (C57BL/6 / 129), mice lacking the pro-apoptotic functions of
cytochrome c (Hao et al., 2005), Apaf-1, caspase-9 and caspase-3 (Kuida et
al., 1996) die with many similar brain defects that include craniofacial
abnormalities, exencephaly, reduced apoptosis and hyperplasia. While a
common phenotype orders these genes in the same pathway, the penetrance
is considerably lower on the C57BL/6 background and many of these
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knockout mice can be viable and fertile (Leonard et al., 2002). The identity
of the strain-specific modifier(s) is unknown.
These findings argue that there may be additional ways of activating
apoptosis or other death programs apart from known pathways. Genetic
arguments place the activation of any such pathway downstream of
mitochondrial control points; Apaf1-null cells expressing BH3-only proteins
can die a caspase-independent death (Cheng et al., 2001), while BAX/BAKdeficient cells are resistant (Wei et al., 2001). Some insights come from C.
elegans and its streamlined version of the apoptotic cell death pathway,
which contains counterparts of BH3-only (egl-1, ced-13), anti-apoptotic
BCL-2 (ced-9), Apaf-1 (ced-4) and a caspase (ced-3). Even in this less
complex system, there are other ways for ced-4 to kill cells independently of
ced-3, the only caspase that appears to function in cell death (Bloss et al.,
2003; Shaham and Horvitz, 1996b). Drosophila may prove to be a valuable
model system too, as novel cell death regulatory mechanisms have been
identified in specialized cells like spermatids (Arama et al., 2003).
Redundant death pathways may substitute for apoptosis during development
as well. Apoptosis is the most studied cell death pathway, but it is certainly
not the only form of programmed cell death (Abraham et al., 2007; Hetz et
al., 2005; Overholtzer et al., 2007).
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1.12 Prologue to the XIAP Δ RING project
The study described here seeks to extend our understanding of IAP
RING functions in mammals. Mammalian XIAP shares several properties
with Drosophila DIAP1, including the ability to bind to caspases, to Reaperfamily proteins, and the ability to undergo auto-ubiquitination and
proteasome-mediated degradation in response to apoptotic stimuli (Yang et
al., 2000). Since these conclusions stem largely from overexpression and in
vitro experiments, we decided to examine the role of XIAP E3-ligase
activity for caspase regulation and apoptosis in vivo. For this purpose, we
used gene targeting to generate a mouse XIAP ΔRING allele which
uncouples the caspase-binding properties of XIAP from the ubiquitin
system.

Removing the RING stabilized XIAP in apoptotic thymocytes,

demonstrating that XIAP E3 ubiquitin-ligase activity is a major determinant
of XIAP protein stability in vivo. However, loss of RING function had no
detectable consequences for thymocyte apoptosis, virtually reproducing the
results from a previous report for XIAP-null mice (Harlin et al., 2001). On
the other hand, ΔRING embryonic stem cells and fibroblasts had elevated
caspase-3 enzyme activity and impaired ubiquitination of active caspase-3
during apoptosis. Furthermore, XIAP ΔRING embryonic fibroblasts were
43

strongly sensitized to TNF-α apoptosis. Therefore, XIAP RING function
appears to play a physiological role in certain cell types, but not others.
Finally, deletion of the XIAP RING also significantly increased apoptosis of
proliferating B-cells and improved the survival of mice in a mouse
lymphoma model.

We conclude that the E3 ubiquitin-ligase activity of

XIAP is important for the regulation of apoptosis in at least some cell types
in vivo, and that this activity contributes to tumor suppression. These results
suggest that the XIAP RING may be a promising drug target for developing
a novel class of cancer therapeutics.
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2 ENGINEERING THE Δ RING
TARGETING

ALLELE BY GENE

2.1 SUMMARY
We devised a strategy to inactivate the mouse XIAP RING ubiquitinligase motif by gene targeting. The RING was deleted by replacing the start
of the domain with stop codons, while preserving the triplicate BIR domains
that can bind and inhibit caspases.

All stages of gene targeting were

successful and a ΔRING colony was established. ΔRING mice were fertile
and born at Mendelian frequencies for gender and genotype. Mutant mice
were phenotypically normal and indistinguishable from wild-type mice
when challenged in vivo by whole-body irradiation or experimental models
of liver failure.
2.2 INTRODUCTION
Gene targeting based on homologous recombination is one of the most
powerful tools in modern mouse genetics. Gene targeting has opened the
mouse genome up to manipulations that range from chromosomal
rearrangements to precise editing of individual codons (van der Weyden et
al., 2002). We decided to use gene targeting to inactivate the XIAP RING
motif for many reasons. First, we wanted to express the ΔRING protein
45

from the endogenous promoter, because XIAP is subject to uncommonly
complex post-transcriptional and post-translational regulation in humans and
mice (Lewis and Holcik, 2005; Vaux and Silke, 2005). Second, we reasoned
this would minimize artifacts that arise when RING mutant constructs are
overexpressed. For example, overexpression experiments in Drosophila
would argue that RING mutations render DIAP1 a better inhibitor of
apoptosis, while the same mutations in the endogenous gene actually cause
lethality because of unrestrained apoptosis (L. Goyal and H. Steller,
unpublished observations). Third, generating a mutant animal would allow
us to address the consequences of RING inactivation in normal mouse
development and disease models. Finally, it was relatively straightforward
to create this allele because the RING is positioned at the far carboxyl
terminus of the protein (Figure 2.1). Thus, we could truncate the XIAP
protein at the start of the RING domain by introducing a stop codon in place
of the codon (C449) that marks the first amino acid of the RING. This
chapter describes the general strategy to generate a mouse XIAP ΔRING
allele that lacks the RING but retains the triplicate BIR domains.
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2.3 EXPERIMENTAL PROCEDURES
2.3.1 Design and construction of the XIAP ΔRING targeting vector
We devised a strategy to eliminate the XIAP RING (located at the far
carboxyl terminus) using a homology-based “knock-in” replacement of the
first two amino acids of the RING (C449 and K450) by stop codons. The
pK-11 plasmid (a gift from Chingwen Yang) served as the backbone for
assembling the ΔRING targeting vector. The targeting vector contained a
removable positive selection cassette (PGK-neomycin phosphotransferase)
in the sense orientation flanked by FRT sites that could be recognized and
excised by the FLPe recombinase.

A superfluous loxP site located

downstream of the selection cassette was removed from pK-11 before
cloning. A single 2.7 kB fragment containing both the final exon (encoding
the RING) and the 2.0 kB 3’ homology arm was amplified by PCR from an
X-chromosome bacterial artificial chromosome (RPCI 23 207E14, C57BL/6
strain). The first two codons of the RING were mutated to tandem stop
codons (opal and ochre) by site-directed mutagenesis and a diagnostic SacI
restriction site was appended immediately downstream from the stop
codons. This fragment was cloned into the SalI/ApaI sites located on the 3’
site of the FRT-Neo-FRT cassette in pK-11. The 5’ homology arm contained
6.0 kB of genomic DNA immediately upstream of the ΔRING mutation. A
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NotI restriction site (for linearizing the vector) was appended to the 5’
terminus during PCR, and the fragment was cloned into the SacII site on the
5’ side of FRT-Neo-FRT.

Finally, a PGK-diphtheria toxin-A negative

selection cassette was amplified by PCR from the vector pDTA (a gift from
Dónal O’Carroll) and ligated in the antisense origin into the KpnI site after
the 3’ homology arm. The Expand High-Fidelity DNA polymerase (Roche)
was used for PCR amplification.
The vector was designed with the FRT-Neo-FRT cassette positioned
in the final intron of the targeted locus, adjacent to the sixth exon encoding
the RING. The final targeted locus (following excision of FRT-Neo-FRT by
FLPe) would thus contain only the introduced stop codons (and diagnostic
restriction site) in the final exon, and one residual intronic FRT site flanked
by the SacII and SalI restriction sites introduced for cloning purposes. We
presumed that this short, 55-nucleotide piece of DNA remaining in the
intron would not affect the synthesis or splicing of the ΔRING mRNA. PCR
genotyping primers that flank the insertion site of the residual DNA were
chosen to distinguish WT from ΔRING alleles based on the larger size of the
PCR product from the ΔRING locus (Forward primer sequence: 5’-TAA
AGC CTT TAC CTT CTT CTC TAT TTC C-3’; reverse primer sequence:
5’-TGG GAC AGG TAG GAT TTA GTG CTT CG-3’; annealing
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temperature of 55 C). The targeting vector was sequenced to confirm that
the vector was assembled correctly and that no other mutations were
introduced during PCR amplification of the BAC DNA template.
2.3.2 Gene targeting, generation of chimeric mice, and establishment of a
ΔRING colony
100 µg of plasmid DNA were digested for 2 hours with NotI to
linearize the vector, and then extracted by ethanol and resuspended in water.
Gene targeting in mouse embryonic stem cells (E14 line, 129/Ola strain) was
conducted by the Rockefeller University Gene Targeting Resource Center
according to standard techniques (Nagy, 2003).

Briefly, ES cells were

electroporated with the linearized DNA, plated on a feeder layer of
mitotically arrested neomycin-resistant fibroblasts, and then cultured in 200
µg/mL G418 to select for neomycin-resistant colonies.

Individual

neomycin-resistant, replica-plated colonies were selected and screened for
homologous targeting of the XIAP locus by Southern blotting of SacI
digested genomic DNA. For this purpose, we used a 312-bp probe created
by PCR from outside the 3’ homology arm (Forward primer sequence: 5’TCG GAA GGT CAC AGA ATA ACC G; reverse primer sequence: 5’CCC AGC GAA TCA CAT TGT AGT CAC; PCR annealing and Southern
hybridization temperature of 55 C). Independently targeted clones were
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expanded on feeder layers and karyotyped. Three ES clones with normal
diploid genomes were injected into C57BL/6 blastocysts and implanted into
pseudopregnant females by the Transgenic Services facility at Rockefeller
University, using standard techniques (Nagy, 2003).
Strongly chimeric male mice (as gauged by the highest penetrance of
the chinchilla coat color modifier gene from the 129/Ola background) were
selected for backcrosses to transgenic C57BL/6 “FLPeR” females,
expressing FLPe from the constitutive ROSA26 locus (Farley et al., 2000), to
remove the neomycin cassette in vivo. FLPeR mice were a gift from Dónal
O’Carroll and genotyped by PCR (Forward primer sequence: 5’-CAC TGA
TAT TGT AAG TAG TTT GC; reverse primer sequence: 5’ CTA GTG
CGA AGT AGT GAT CAG G) according to the published protocol (Farley
et al., 2000).
The presence of any agouti pups in the litters indicated germline
transmission of the mutant allele; this was confirmed by Southern blotting of
tail biopsy DNA. Excision of the Neo cassette in progeny was assessed by
Southern blotting of ApaLI digested genomic DNA from tail biopsies, using
the same probe described above, and also by PCR using the genotyping
primers.

Animals positive for the mutant allele and Neo excision, and

negative for the FLPe transgene, were selected to establish the colony.
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Initial experiments were conducted using mice on a mixed 129/Ola /
C57BL/6 genetic background. A congenic strain was established on the
C57BL/6 background by serial backcrossing for over ten generations.
Animals were housed in a specific pathogen free environment with
unlimited access to food and water in the LARC vivarium at the Rockefeller
University. The institutional animal care and use committee approved all
experiments under animal protocols 04-058 and 07-059.
2.3.3 Aging and irradiation experiments
Aging cohorts of male mice on a mixed 129/Ola / C57BL/6
background (WT, n=14; ΔRING, n=19) were set aside and monitored
periodically for the incidence of disease or death. Another cohort of mice
derived after backcrossing to the C57BL/6 background for at least 5
generations (n=13 for both genotypes) was selected for an in vivo irradiation
experiment. Mice were administered antibiotics (30 mg/L neomycin, 30
mg/L kanamycin, 10 mg/L gentamicin) in their drinking water for two days
prior to a single 7-Gy dose of ionizing radiation from the LARC X-ray
source (1.8 Gy/min). Irradiated mice were given continued access to the
antibiotic drinking water and monitored for survival over time. KaplanMeier survival curves were constructed and analyzed with a log-rank
statistical test in the Prism 4.0 software package (GraphPad Software, Inc.).
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We also submitted pairs of littermate mice that ranged in age from 50
to 150 days for complete histopathological analysis by the Laboratory of
Comparative Pathology at the Memorial Sloan-Kettering Cancer Institute.
The pathologists were not informed of the genotypes of the mice or the
nature of the project to ensure an unbiased examination.
2.3.4 TNF-α and Fas-dependent liver apoptosis
Agonstic anti-Fas antibody (10 µg Jo-2 antibody [BD Biosciences] in
200 µL sterile phosphate-buffered saline [PBS]), or 300 ng TNF-α
(Peprotech) and 20 mg D-galactosamine (GalN; Sigma) in 200 µL PBS, was
administered to age-matched mice by lateral tail vein injection. Mice were
sacrificed by cervical dislocation, at a time (Fas, 4 hours; TNF-α/GalN: 6
hours) when mice were moribund but still alive. Livers were surgically
removed and snap-frozen in liquid nitrogen. Livers were homogenized in
lysis buffer (10 mM Tris [pH 7.5], 100 mM NaCl, 1mM EDTA, 0.01%
Triton X-100) using a Polytron (Kinematica) and clarified by centrifugation
at 14,000 RPM for 10 minutes at 4 C, before determining total protein
concentration using the Bradford reagent (Bio-Rad). 150 µg of total protein
from each sample were assayed for caspase-3 activity in bulk by measuring
the linear rate of cleavage of a fluorescent Z-DEVD-R110 substrate using
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the EnzChek Caspase-3 Assay Kit #2 (Invitrogen) and a SpectraMax M2
multiwell plate reader (Molecular Devices).
2.3.5 Statistical treatments
All bar graphs values are displayed as means with standard error unless
noted otherwise.
2.4 RESULTS
2.4.1 Generation of ΔRING mice by gene targeting and blastocyst injection
We used homology-based gene targeting in mouse embryonic stem
(ES) cells to create a XIAP ΔRING mutant allele by replacing the first two
amino acids (C449 and K450) of the RING domain with stop codons (Figure
2.1). This mutation was designed to truncate the RING and the thirteen
amino acid sequence between the end of the RING and the carboxyl
terminus, while leaving intact the triplicate BIR domains in the aminoterminal half of XIAP. After targeting the XIAP locus in the E14 embryonic
stem (ES) cell line with a conventional replacement strategy, 6 of 96
neomycin-resistant ES colonies showed restriction fragment length
polymorphisms consistent with precise homologous targeting; an example
Southern blot autoradiograph is shown in Figure 2.2A. Correct insertion of
the stop codons was confirmed by directly sequencing genomic DNA from
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Figure 2.1 Gene targeting strategy. WT XIAP protein structure is shown at
top. Second line: genomic organization of the XIAP locus, indicating WT
stop codon and the location of the Southern probe. Third line: targeting
vector, indicating ΔRING stop and FRT sites (open triangles); DTA denotes
negative selection cassette. Third line: Targeted ΔRING (Neo) locus. Fourth
line: Final ΔRING (ΔNeo) locus after FLPe excision of Neo; grey
arrowheads indicate location of genotyping primers that flank residual FRT
site. ΔRING XIAP protein structure is shown at bottom.
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Figure 2.2 Gene targeting results. (A) Southern blot of SacI-digested DNA
from Neo-resistant ES colonies using the probe in Figure 2.1; numbers
indicate individual colonies (B) Southern blot of SacI-digested tail biopsy
DNA. (C) Southern blot of ApaLI-digested DNA from mice crossed to
FLPeR deletor strain. (D) PCR genotyping of mice. (E) DNA sequencing
chromatograph from Exon 6 in WT and ΔRING alleles in ES cells; asterisks
indicate stop codons. (F) DNA sequence of residual intronic DNA in ΔRING
allele.
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targeted clones (Figure 2.2E). We decided to remove the Neo cassette in
vivo to minimize the time ES cells spent in culture; therefore, the ES cells
used for blastocyst injection had the genomic organization shown in the

ΔRING (Neo) line in the targeting schematic (Figure 2.1).
Two of three independently targeted clones with normal diploid
karyotypes (#49, #129) yielded mice with strongly chimeric coat colors after
blastocyst injection and implantation into foster mothers from the C57BL/6
inbred strain; a third clone (#165) produced no chimeras. Chimeric males
from both founder lines (line 49: 3 of 7 chimeras; line 129: 5 of 11 chimeras)
transmitted the mutant allele through the germline when backcrossed to
C57BL/6 “FLPeR” females expressing the FLPe recombinase. This was
evident by the presence of pups with the dominant agouti coat color and
verified by Southern blotting of SacI digested DNA tail biopsies (Figure
2.2B). Excision of the Neo cassette was confirmed in these animals by
Southern blotting of ApaLI digested DNA (Figure 2.2C).

This was

corroborated by PCR genotyping across the residual FRT site in a Neodeleted locus (Figure 2.2D) and direct DNA sequencing (Figure 2.2F).
Collectively, the genotyping results confirmed that we had derived mice
with the final, correctly targeted XIAP ΔRING (ΔNeo) locus. Mice derived
from targeted clone #129 were chosen arbitrarily to found the colony.
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2.4.2 Analysis of an aging cohort of mice

ΔRING mice were fertile and born at expected Mendelian ratios for
gender and genotype (Table 1). We submitted age-matched wild-type and
mutant mice (mixed 129/Ola / C57BL/6 genetic background) for

Sex
Female

Number
in litters
42

Predicted
number
40

Male

38

40

Genotype

Number with
genotype
WT/WT
19
WT/ΔRING
23
WT/ΔRING/-

18
20

Predicted
20
20
20
20

Table 1 Distributions of gender and genotype in ΔRING litters. Tally of
the number of mice of different gender and genotype in 11 litters (n=80
mice). Parental crosses: WT/- male x WT/ΔRING female.

comprehensive, unbiased histopathological examinations by an outside
laboratory.

ΔRING mice were indistinguishable from WT littermates at

different ages when examined in a blind manner. Moreover, ΔRING mice
have shown no overt susceptibility to disease or premature death in our
pathogen free mouse colony after more than 24 months of age (Figure 2.3).
These observations are consistent with those of XIAP-null mice, which
develop mostly normally (Harlin et al., 2001; Olayioye et al., 2005). These
results argue that the RING domain was dispensable for fertility and normal
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development on this mixed genetic background. We derived a congenic
mutant strain by repeatedly backcrossing (n>10 generations) to the C57BL/6
inbred strain; these mice are also fertile and phenotypically normal.
2.4.3 Whole-body irradiation
Treatment of mice with a single whole-body dose of ionizing radiation
leads to mortality over the course of roughly two weeks, probably in
response to p53-dependent apoptosis of all hematopoietic precursors in the
bone marrow, in addition to other radiosensitive renewable tissues
(Westphal et al., 1998). We irradiated a cohort of WT and mutant mice to
determine if loss of the RING domain influenced survival in a paradigm of
DNA damage induced apoptosis. The survival curves for mice of both
genotypes were comparable following a single 7-Gy dose of X-irradiation
(Figure 2.3). The median survival time for WT mice was 12 days and 11
days for ΔRING mice. Since survival kinetics were unaltered in mutant
mice, the loss of XIAP E3 ubiquitin-ligase activity did not affect death that
occurs following DNA damage caused by X-irradiation in vivo.
2.4.4 In vivo hepatocyte apoptosis
Antibodies against the Fas death receptor function as agonists that trigger
Fas-dependent apoptosis in hepatocytes when administered intravenously
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Figure 2.3 Aging and Whole-Body Irradiation Survival Curves. (A)
Kaplan-Meier survival curve of an aging cohort of mice; p=0.25. (B)
Kaplan-Meier survival curve of mice following 7-Gy of whole-body
irradiation; p=0.44. Log-rank test was used for significance.
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(Ogasawara et al., 1993). Likewise, administration of the TNF-α cytokine in
combination with an inhibitor of transcription (e.g., D-galactosamine,
“GalN”) provokes acute hepatitis accompanied by severe apoptosis,
ultimately leading to the death of the animal within hours (Leist et al., 1994).
Both are models for death receptor apoptosis in vivo.

Although the

downstream effector pathways are distinct for Fas- and TNF-α-dependent
apoptosis, activation of either pathway leads to caspase-3 activation. We
administered either treatment to WT and ΔRING mice to see if the RING
domain influenced these in vivo paradigms of hepatocyte apoptosis.
Animals were sacrificed 4 hours after Fas or 6 hours after TNF-α/GalN
treatment and assayed for caspase-3-like activity in the liver, as an endpoint
readout for hepatocyte apoptosis. WT and ΔRING mice showed comparable
caspase-3 activity in response to these treatments.

WT mice became

moribund roughly at the same time as ΔRING mice. Although we did not
perform any TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP
nick end labelling) to corroborate the caspase assay, these experiments show
that deletion of the RING domain did not affect caspase activity in vivo in
response to different death receptor signaling paradigms.
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Figure 2.4 Liver apoptosis. Caspase-3-like activity measured in liver
lysates after tail vein injections.
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2.5 DISCUSSION
The results shown here imply that XIAP ubiquitin-ligase function was
dispensable for development and survival on mixed and congenic
backgrounds. The XIAP ΔRING mouse is similar in these respects to the
two XIAP-null mice that have been engineered, neither of which displays
any severe developmental defects (Harlin et al., 2001; Olayioye et al., 2005).
To date, the only phenotype described at the level of the whole animal is
delayed lobuloalveolar development in the mammary gland, but XIAP-null
dams are still able to nurse litters (Olayioye et al., 2005). The lack of an
apoptosis phenotype in the liver following Fas or TNF-α/GalN
administration contrasts with the results presented in Chapter 5, where a
sensitivity to TNF-α-dependent apoptosis is described in embryonic
fibroblasts.
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3 APOPTOSIS IN ΔRING THYMOCYTES AND OTHER
PRIMARY HEMATOPOETIC CELLS
3.1 SUMMARY
The evidence that RING domains promote IAP turnover was first
uncovered by studying mouse thymocytes undergoing apoptosis. We used

ΔRING thymocytes to test the hypothesis that RING-mediated turnover can
facilitate cell death. The RING was the principal determinant of XIAP
stability during thymocyte apoptosis. This is consistent with the notion that
the XIAP RING functions as an E3 ubiquitin-ligase to promote XIAP
turnover. Enhancing XIAP stability by removing the RING did not affect
caspase activation or activity, and ΔRING thymocytes underwent normal
apoptosis. T- and B-cell development in the thymus and bone marrow,
respectively, was unaltered in ΔRING mice. Collectively, these data imply
that the RING was important for XIAP stability, but increasing the
abundance of XIAP by deleting the RING did not impede apoptosis or alter
hematopoietic development.
3.2 INTRODUCTION
3.2.1 General comment on apoptosis in immunity
Cell death pathways regulate the development and homeostasis of the
immune system.

Virtually every step in B- and T-cell development is
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governed by checkpoints that can activate apoptosis when developmental
programs go awry, thereby eliminating non-functional or auto-reactive
lymphocytes. Lymphocyte survival depends on the proper integration of
cell-autonomous and external signals. Lymphocyte apoptosis involves both
mitochondrial- and receptor-dependent death pathways (Rathmell and
Thompson, 2002). These pathways function in development and maturation
of lymphocytes, and to attenuate the immune response after an infection
(Opferman, 2007). Proper regulation of apoptosis in the lymphoid system is
important for preventing autoimmunity and cancer as well (Krammer, 2000).
3.2.2 Apoptosis in developing lymphocytes
T-cell development is regulated by control checkpoints that can
trigger cell death to maintain the quality of the T-cell pool.

T-cell

progenitors originate in the bone marrow but hone to the thymus for
development and maturation (Jotereau et al., 1987) (Carlyle and ZunigaPflucker, 1998).

Stringent quality control results in the death of

approximately 97% of developing T-cells in the thymus without any evident
inflammation (Shortman et al., 1990). Indeed, a high index of apoptosis is
seen in situ, while apoptotic thymocytes are cleared very rapidly (Surh and
Sprent, 1994).

Apoptosis is evident at the earliest stages of thymocyte

development as T-cell precursors compete for the survival factor interleukin64

7 (Baird et al., 1999): cells deprived of interleukin-7 undergo apoptosis that
depends on the BH3-only gene BIM (Bouillet et al., 1999) and is blocked by
BCL-2 overexpression (von Freeden-Jeffry et al., 1997).
One of the hallmark events of T-cell development is the somatic
rearrangement of T-cell receptor (TCR) genes to create specificities for
diverse antigens. Thymocytes that fail to arrange a functional TCR undergo
“death by neglect”, although the molecular mechanism remains unclear
(Ashwell et al., 2000). A prevailing hypothesis holds that signaling through
the TCR, possibly transduced by Ras through the ERK (extracellular signalrelated kinase) effector pathway (Alberola-Ila et al., 1996), rescues
thymocytes from apoptosis that would otherwise occur by default in
response to ambient glucocorticoids in the thymic microenvironment
(Zacharchuk et al., 1990). Thymocytes expressing a functional TCR escape
death by neglect, upregulate the CD4 and CD8 surface antigens, and become
subject to positive and negative selection.
The TCR recognizes antigens presented by major histocompatibility
complexes (MHC) on dendritic cells and macrophages, and this interaction
is necessary for T-cell function. A TCR that recognizes a MHC with the
proper avidity initiates Ras survival signalling in the process known as
positive selection (Yang and Ashwell, 1999).

65

Cells that fail positive

selection die in the thymus (Huesmann et al., 1991) (Merkenschlager et al.,
1997). Negative selection eliminates T-cells that bind a cognate MHC too
tightly and helps ensure a pool of self-tolerant T-cells (Kappler et al., 1987).
Thymocytes that undergo positive selection and survive negative selection
proceed to downregulate either CD4 or CD8 to become cytotoxic or helper
T-cells, respectively, and migrate to the periphery.
The mitochondrial pathway of apoptosis has a prominent role in
thymocyte apoptosis. Negative selection depends on the BH3-only protein
BIM, as BIM-null mice fail to eliminate many self-reactive thymocytes
(Bouillet et al., 2002) and develop autoimmunity (Bouillet et al., 1999).
BAX and BAK together control most of the death that occurs in T-cell
development, and mice genetically deficient for both genes accumulate Tlymphocytes across many developmental stages (Lindsten et al., 2000).
BCL-2 overexpression inhibits the death of double-positive thymocytes that
do not undergo positive selection (Strasser et al., 1994), but not death by
neglect that occurs in the absence of a functional TCR (Maraskovsky et al.,
1997).

BCL-2 overexpressing thymocytes remain self-tolerant, so other

mechanisms are likely in place to ensure deletion of autoreactive thymocytes
(Sentman et al., 1991).
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Analogous apoptotic checkpoints function during B-cell development,
which occurs primarily in the bone marrow. B-cells also depend on cytokine
signaling for survival and to avoid death by neglect (Baird et al., 1999).
Developing B-cells that receive sufficient interleukin-7 upregulate the
antiapoptotic BCL-2 family member, MCL1, and this is believed to impart
resistance to apoptosis at this developmental stage (Opferman et al., 2003).
Apoptosis functions in eliminating B-cells that do not generate a functional,
self-tolerant B-cell receptor during development in the bone marrow
(Melchers et al., 2000). As with T-cells, the death of autoreactive B-cells
depends largely on BIM (Bouillet et al., 1999), and almost entirely on BAX
and BAK (Takeuchi et al., 2005). BCL-2 overexpression prevents many of
these deaths (Hartley et al., 1993).
3.2.3 Apoptosis in peripheral T- and B-cells
The numbers of peripheral lymphocytes are tightly controlled, in large
part by apoptosis that balances out proliferation in cells involved in antigendependent immune responses. Death receptor signaling appears to have a
more prominent role in maintaining homeostasis in the periphery than it does
during lymphocyte development (Rathmell and Thompson, 2002).

For

example, Fas death receptor signaling instructs the death of clonal
populations of activated T-cells in a waning immune response (Krammer,
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2000). Mice and humans with deficiencies in the Fas receptor pathway
develop autoimmunity and accumulate peripheral self-reactive lymphocytes.
Mice that lack both Fas and BIM show the most striking accumulation of
peripheral T-cells (Hughes et al., 2008), which points to the combined
effects of these pathways in regulating immune homeostasis. Antibodyproducing plasma B-cells also die during a waning immune response. The
molecular underpinnings of death in these cells probably involve both Fas
and BIM as well (Hutcheson et al., 2008; Rothstein et al., 1995).
3.2.4 Roles of IAPs in thymocyte apoptosis
The first functions described for the XIAP and cIAP1 RING domains
were the capacity to serve as E3 ubiquitin ligases that promote
autoubiquitination and IAP degradation during mouse thymocyte apoptosis
(Yang et al., 2000). Additionally, a ΔRING XIAP mutant protein is resistant
to ubiquitination, stably expressed, and imparts resistance to apoptosis when
expressed in a mouse T-cell hybridoma (Yang et al., 2000).

The

observation that efficient thymocyte apoptosis requires the proteasome
(Grimm et al., 1996) led to a hypothesis that IAP RINGs may act
proapoptotically in these cells by engaging the ubiquitin system to relieve a
break on cell death pathways by degrading IAPs (Yang and Li, 2000).
Studies on DIAP1 in Drosophila provide a precedent for a pro-apoptotic
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RING function during apoptosis.

Expression of the DIAP1 antagonist

Reaper depletes DIAP1 through RING-dependent autoubiquitination,
leading to apoptosis in the wing imaginal disc (Ryoo et al., 2002).
Furthermore, Ubcd1, the cognate E2 ubiquitin-conjugating enzyme for
DIAP1, is required for Reaper-dependent apoptosis (Ryoo et al., 2002).
Thymocytes from mice deficient in XIAP, cIAP1 or cIAP2 are not
strongly sensitized to apoptotic stimuli in vivo or under culture conditions,
although there are subtle reductions in thymus size in cIAP1-null mice
(Conte et al., 2006; Conze et al., 2005; Harlin et al., 2001). In contrast, the
total thymocyte count increases and T-cells accumulate in the spleen when
human XIAP is expressed transgenically in mice by the thymocyte-specific
lck promoter (Conte et al., 2001). Thymocytes from the lck-XIAP transgenic
mouse are also resistant to diverse apoptotic stimuli in vivo and in culture,
including an experimental mimic of negative selection and glucocorticoid
treatment. The CD4:CD8 (single-positive) T-cell ratio is also inverted in the
thymus; similar observations are seen in lck-Bcl2 mice (Sentman et al.,
1991). The authors attribute the resistance to apoptosis to the increased
stability of human XIAP overexpressed from the mouse lck promoter (Conte
et al., 2001).

Therefore, data from transgenic mice suggest that the
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persistence of stabilized XIAP during thymocyte apoptosis may inhibit
death.
In this chapter, we describe experiments designed to test the
hypothesis that the XIAP RING can act pro-apoptotically in thymocytes by
serving as a ubiquitin-ligase to direct XIAP downregulation. We reasoned
that genetic deletion of the RING would prevent autoubiquitination and
ubiquitination in trans by other IAPs (Silke et al., 2005), and that stabilized
XIAP may impair lymphocyte cell death by continuing to inhibit caspases.
3.3 EXPERIMENTAL PROCEDURES
3.3.1 Isolation and culture of primary lymphocytes
Adolescent (4-6 week old) littermate mice were selected for
thymocyte experiments because the thymus undergoes involution and
decreases in size after adolescence. Animals were sacrificed using CO2 gas
and thymic lobes were dissected under sterile conditions in 2% (v/v) fetal
bovine serum (FBS; Hyclone) in PBS (pH 7.4).

Single cell thymocyte

suspensions were prepared by mincing thymi in FBS/PBS through a 40 µm
nylon mesh cell strainer. Cells were collected by centrifugation (3 minutes,
1000 RPM, 4 C), then treated with erythrocyte lysis buffer (9 volumes of
150 mM NH4Cl, 1 volume of 130 mM Tris-Cl [pH 7.65]) for 3 minutes at
room temperature. Thymocytes were collected again by centrifugation and
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resuspended in thymocyte medium (RPMI medium supplemented with 10%
FBS, 100 U/mL penicillin [Gibco], 100 µg streptomycin [Gibco], and 2 mM
L-Glutamine[Gibco]) at a density of 5 x 106 cells/mL, generally in T25
flasks or 6-well plates.
B-cells were purified from spleens by first creating single-cell
splenocyte preparations and lysing erythrocytes as described above. Cells
were resuspended at a density of 1 x 107 cells per 40 µL FBS/PBS and
incubated for 10 minutes at 4 C with a biotin-conjugated antibody cocktail
that labelled the predominant non-B-cell populations in the spleen
(Miltentyi). Non-B-cells were labelled secondarily with anti-biotin magnetic
beads and depleted by flowing samples through a magnetic column. Isolated
splenic B-cell populations in the flow-through were used for downstream
assays; purity was verified by fluorescent immunostaining and flow
cytometry as described below.

B-cells were cultured in B-cell medium

(45% Iscove's MEM, 45% DMEM, 10% FBS, 100 U/ml penicillin, 100 g/ml
streptomycin, 4 mM l-glutamine, and 25 µM β-mercaptoethanol [Sigma]) at
37 C and 5% CO2.
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3.3.2 Apoptosis assays
Thymocytes were treated in culture with 10 µM etoposide (Sigma) or
1 µM dexamethasone (Sigma) to induce apoptosis, or left untreated in
thymocyte medium as a control for spontaneous death under cell culture
conditions. Thymocytes were also treated with 100 ng/mL TNF-α with and
without 10 µM cycloheximide (Sigma). B-cells were treated with 10 µM
etoposide or left untreated in B-cell medium. For some experiments, the
peptide aldehyde proteasome inhibitor MG-132 (Calbiochem) or the pancaspase inhibitor zVAD-fmk (Alexis) was added at a final concentration of
20 µM.
3.3.3 FLICA labeling of the caspase-3 active site
To analyze of caspase-3 activation, thymocytes were treated with
dexamethasone or left untreated in 96-well plates for 5 or 7 hours, then
incubated with the FAM-DEVD-FMK FLICA (caspase-3, principally) or
FAM-LEHD-FMK (caspase-9, but crossreacts with other caspases) reagent
(Immunochemistry Technologies; diluted from 150X stock) for an additional
hour. Unbound FLICA reagent was removed by pelleting cells through
centrifugation in the 96-well plate, decanting the medium, and washing
twice with the 1X wash buffer supplied in the FLICA kit.
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Cells were

resuspended in 100 µL wash buffer supplemented with 40 ng/mL propidium
iodide (PI).

The number of apoptotic cells was determined with a

FACScalibur flow cytometer (BD Biosciences) by gating PI-negative,
carboxyfluorescein-positive cells among at least 4000 total cells.
3.3.4 Annexin-V/propidium iodide and TUNEL apoptosis assays
Thymocytes were treated with dexamethasone or left untreated in
thymocyte medium in 96-well plate for 8 hours, then collected by
centrifuging the entire plate and decanting culture medium. For TUNEL,
cells were washed twice in 0.5% bovine serum albumin (BSA; Sigma) in
PBS (pH 7.4) and fixed in 2% paraformaldehyde for 10 minutes at 37 C.
Cells were washed twice in BSA/PBS and permeabilized in 70% ethanol for
30 minutes at -20 C.

Cells were washed twice in BSA/PBS before

performing the TUNEL reaction for 60 minutes at 37 C according to the
manufacturer’s directions (MBL International). Cells were washed again
before flow cytometry. The percentage of apoptotic cells was determined by
counting the number of fluorescein-positive cells among 4000 cells per
sample. For annexin-V/propidium iodide labelling, cells were collected and
labelled in flow cytometry tubes (100 µL) with 4 µL propidium iodide (50
µg/mL stock) and 2 µL annexin-V-FITC (BD Biosciences) for 10 minutes at
room temperature before flow cytometry.
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3.3.5 Caspase-3-like (DEVDase) enzyme activity assay
3x107 thymocytes were treated in T25 flasks with etoposide or
dexamethasone, or left untreated, for 8 hours before collecting cells by
centrifugation. Cell pellets were first frozen at -80 C and then lysed in
DEVDase assay lysis buffer (described in Chapter 2) for 20 minutes on ice.
Lysates were clarified by centrifuging tubes for 5 minutes at 5000 RPM at
room temperature, and the protein concentrations were determined using the
Bradford reagent (Bio-Rad). Bulk caspase-3-like activity was determined
from 50 µg total protein as described in Chapter 2.
3.3.6 Immunoblotting
Cells were homogenized in lysis buffer (20 mM Tris [pH 7.5], 150
mM NaCl, 1mM EDTA, 1 mM EGTA, 1% Triton X-100) supplemented
with protease inhibitors (1 mM PMSF, 2 µg/mL leupeptin, 100 nM
benzamidine, 1 µM pepstatin A). Lysates were incubated on ice for 30
minutes and clarified by centrifugation (14,000 RPM, 10 minutes, 4 C)
before normalizing protein concentrations using the Bradford assay. Protein
samples were resolved on SDS-PAGE Ready Gels (Bio-Rad) and
electroblotted on Immobilon-P membranes (Millipore). Membranes were
blocked for one hour at room temperature in blocking buffer (5% [w/v]
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nonfat milk in 0.5% [v/v] Tween 20/PBS) and incubated overnight at 4 C
with antibodies dissolved in blocking buffer. Membranes were washed with
0.5% Tween 20/PBS wash solution, incubated for 30 minutes at room
temperature

with

appropriate

secondary

antibodies

(conjugated

to

horseradish peroxidase and diluted in blocking buffer), before washing
again. Signals were detected with the West Femto chemiluminescent kit
(Pierce Biotechnology) on Bio-Max film (Kodak).
3.3.7 Analyzing the cellular compositions of the thymus, spleen and bone
marrow
The distribution of major thymocyte subpopulations was determined
in single-cell suspensions by flow cytometry, using fluorescently labelled
antibodies against surface markers CD4 and CD8. Total cell counts in the
thymus were calculated using a hemocytometer. The spleen was analyzed in
an analogous manner by creating single-cell splenocyte suspensions and
lysing erythrocytes, then staining with antibodies directly conjugated to
fluorophores. The composition of the bone marrow was determined by
flushing the marrow from femurs and tibias, treating with erythrocyte lysis
buffer and staining with antibodies. Cells were labelled with antibodies (BD
Biosciences) for 20 minutes on ice; dilutions were CD19-FITC (1:100);
CD90-PE (1:100); B220-APC (1:50); IgD-FITC (1:100); IgM-PE (1:200);
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CD43-FITC (1:100); CD8-FITC (1:100); CD4-PE (1:200); cKIT-FITC
(1:100); Sca1-PE (1:200).
3.4 RESULTS
3.4.1 RING ubiquitin-ligase activity was the primary determinant of XIAP
stability during thymocyte apoptosis
If RING-mediated downregulation of IAPs is necessary for efficient
apoptosis, we reasoned that genetic deletion of the XIAP RING would allow
us to determine if IAP RINGs can act pro-apoptotically. Indeed, ΔRING
XIAP was more stable than full-length XIAP in cultured thymocytes dying
in response to the glucocorticoid dexamethasone, a physiological trigger of
cell death, or the topoisomerase inhibitor etoposide, which elicits DNA
breaks (Figure 3.1A). The basal expression of ΔRING XIAP was greater,
and it was cleaved over time during apoptosis. Deletion of the RING did not
alter the basal expression or downregulation of cIAP1 during apoptosis
(Figure 3.1A). XIAP and cIAP1 can bind each other in a RING dependent
manner (Silke et al., 2005), and our genetic evidence showed that the XIAP
RING did not influence the abundance of cIAP1 in thymocytes. This result
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Figure 3.1 The RING was the primary determinant of XIAP stability in
thymocytes and splenocytes. (A) Immunoblotting of WT and ΔRING
thymocytes treated with etoposide, dexamethasone or left untreated for
indicated times. (B) Immunoblotting of thymocytes treated for 8 hours with
etoposide or dexamethasone, with or without the proteasome inhibitor MG132 or the pan-caspase inhibitor zVAD-fmk. (C) Splenocytes were treated
with etoposide for 8 hours or left untreated before immunoblotting. n.s.
indicates a non-specific band detected by the XIAP antibody in B-cells, used
as a loading control.
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is consistent with the finding that cIAP1 expression is unchanged in XIAPnull thymocytes (Conze et al., 2005). It is unclear if XIAP ubiquitinates its
binding partner Smac/DIABLO (Creagh et al., 2004; MacFarlane et al.,
2002). Smac/DIABLO expression was unchanged in non-apoptotic ΔRING
thymocytes and it was still downregulated during apoptosis (Figure 3.1A).
Although XIAP can ubiquitinate active caspase-3 in certain situations and
this can lead to decreased subunit abundance (Suzuki et al., 2001), we found
caspase-3 was activated with comparable kinetics and to similar extents
(Figure 3.1A).
Consistent with prior reports (Yang et al., 2000), a peptide aldehyde
inhibitor of the proteasome, MG-132, blocked the decrease of full-length
XIAP during apoptosis while the pan-caspase inhibitor zVAD-fmk had
negligible effects (Figure 3.1B).

In striking contrast, ΔRING XIAP

expression was far more sensitive to caspase inhibition, as zVAD-fmk fully
prevented the decrease in protein levels and abolished the cleavage product,
while MG-132 had a much lesser effect by comparison (Figure 3.1B). This
result supports the hypothesis that the RING engages the ubiquitin system to
promote

XIAP

turnover

in

apoptotic

thymocytes.

cIAP1

and

Smac/DIABLO protein levels were not affected by the RING deletion, and
they remained labile during apoptosis (Figure 3.1A). This leaves open the
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possibility that other IAP E3-ligases may be responsible for targeting these
proteins for degradation.
We also isolated splenocytes (a heterogeneous population of
approximately 50% B-cells and 30% T-cells; see Figure 3.6) and cultured
them with etoposide to induce apoptosis.

We also observed enhanced

stability of ΔRING XIAP during apoptosis in splenocytes (Figure 3.1C).
PARP (poly ADP-ribose polymerase) cleavage was used as a readout for
caspase-3 activity; the native 100 kDa form of PARP was cleaved similarly
in WT and ΔRING cells as splenocytes died spontaneously in the culture
medium and in response to etoposide (Figure 3.1C).
3.4.2 Genetic deletion of the XIAP RING did not influence thymocyte
apoptosis
We next asked if stabilizing XIAP had any impact on thymocyte cell death,
since ΔRING XIAP efficiently blocks glucocorticoid-induced apoptosis
when expressed ectopically in a T-cell hybridoma (Yang et al., 2000). We
counted the numbers of cells harboring active caspases using fluorescent
inhibitor of caspases (FLICA) reagents that covalently label caspase active
site cysteines with fluorophores. We used a FAM-DEVD-FMK reagent to
label effector caspases (principally caspase-3, but also -6 and -7 to lesser
extents) or a FAM-LEHD-FMK reagent to label caspase-9 (though it cross-
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Figure 3.2 FLICA labeling of thymocyte active caspases. Histogram plots
of fluorescence intensity after caspase active sites were labeled with FLICA
affinity tags in thymocytes treated as indicated.
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reacts with other caspases). We did not see any differences in caspase
induction using these reagents when thymocytes were induced to die with
dexamethasone or left untreated for different times (Figure 3.2). Moreover,
caspase-3 enzyme activity was comparable in both untreated and apoptotic
WT and ΔRING (Figure 3.3A). These results show that deleting the XIAP
RING did not affect caspase activation or activity in thymocytes.
We characterized apoptosis using annexin-V/propidium iodide (“PI”)
labelling as a readout for membrane integrity, and TUNEL as a readout for
cleavage of genomic DNA largely dependent on and downstream of
caspase-3 (Woo et al., 1998).

Neither annexin-V/PI (Figure 3.3B) nor

TUNEL (Figure 3.3C) revealed any differences in etoposide- or
dexamethasone-induced apoptosis in ΔRING thymocytes. This finding is in
line with our results showing unaltered caspase activation and activity in
mutant cells. We also cultured thymocytes for 24 hours to characterize the
amount of spontaneous death ex vivo. AnnexinV/PI staining showed no
difference in apoptosis in this situation, and FLICA staining revealed that
effector caspases were activated similarly (Figure 3.3D).

Additionally,

treating cells with TNF-α with or without cycloheximide (CHX) did not
reveal any differences in apoptosis. CHX alone prevented cell death in these
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Figure 3.3 Lack of apoptosis phenotype in Δ RING thymocytes. (A) Bulk
caspase-3-like activity after 8 h treatment. (B) Annexin-V/propidium iodide
labeling of untreated or treated thymocytes after 8h. (C) TUNEL of
apoptotic thymocytes after 8h. (D) Annexin-V/propidium iodide labeling
and FLICA staining of thymocytes left untreated for 24h. (E) TUNEL in
thymocytes treated with TNF-α/CHX.
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Figure 3.4 Apoptosis in B-cells. Purified B-cells were treated as indicated
then assayed for caspase-3 activation by indirect immunofluorescence (A) or
TUNEL (B).
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cells, which suggests that a pro-apoptotic factor may need to be synthesized
for effective thymocyte apoptosis to ensue (Figure 3.3E). We also purified
B-cells from the spleens of WT and ΔRING mice to study apoptosis in this
cell type. Isolated B-cells of both genotypes activated caspase-3 (Figure
3.4A) and underwent apoptosis (Figure 3.4B) similarly when treated with
etoposide or left untreated (Figure 3.4).
Collectively, the data here imply that the RING was important for
XIAP protein stability in thymocytes, but that its removal affected neither
the induction of caspases nor apoptosis in response to several stimuli. In this
cell type, removing XIAP RING function did not reveal any specific proapoptotic role for ubiquitin-mediated XIAP turnover during cell death.
3.4.3 Lymphoid compartments were distributed normally in ΔRING mice
Defective apoptosis can cause imbalances in the cell numbers and cell
distributions of sites where lymphocytes mature and accumulate, because
cell death regulates development in hematopoietic cells (Opferman, 2007).
We determined the cellular compositions of the thymus, spleen and bone
marrow in mutant mice to see if genetic deletion of the RING altered
lymphocyte development in situ. The developing T-cell compartment in the
thymus was normally distributed in ΔRING mice, as assessed by surface
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staining of CD4 and CD8 antigens (Figure 3.5); cells bearing either or both
of these surface makers constitute nearly all of the thymocyte populations.
Double-positive thymocytes formed the bulk of cells, and single-positive
cells were normally abundant.

Moreover, total thymocyte counts were

unperturbed in mutant mice (Figure 3.5). The normal composition of the
thymus may reflect the lack of any clear apoptosis defects in cultured
thymocytes. Our results accord with a previously published description of
XIAP-null mice that does not note any defects in thymocyte development
(Harlin et al., 2001).
The B-cell lineage differentiates in the bone marrow after embryonic
development. We investigated the distribution of major cell types in the
bone marrow using combinations of fluorophore-conjugated antibodies
against major surface markers (Figure 3.5). Hematopoietic stem cells (LSK, Sca1+,cKit+), pro-B cells (B220+, CD43+) and pre-B cells (B220+, CD43) were present in the bone marrow of ΔRING mice in similar proportions as
WT mice.

The numbers of mature and immature B-cells were also

comparable. Spleens from mutant mice showed normal distributions of the
major lymphocyte types (Figure 3.6). The cell types we examined included:
B-cells (B220+, CD90-) and T-cells (B220-, CD90+); immature (B220 low,
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Figure 3.5 Normal thymus and bone marrow in ΔRING mice.
Distributions of cell types as inferred by direct fluorescent labeling of cell
surface proteins.
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Figure 3.6 Normal spleens in ΔRING mice. Cellular composition of the
spleen as inferred from direct immunofluorescent labeling of surface
antigens
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IgM+) and mature (B220 high, IgM+) B-cells; and helper-T (CD4+, CD8-)
and cytotoxic-T (CD4-, CD8+) cells (Figure 3.5B).

Taken together, these

results indicate that deletion of the RING domain did not alter major
lymphoid compartments in mice.
3.5 DISCUSSION
We used thymocytes genetically deficient for XIAP RING ubiquitinligase function to test the hypothesis that RING domains promote IAP
degradation through autoubiquitination (Yang et al., 2000). A prevailing
notion holds that RING-mediated degradation of IAPs might underlie
apoptosis in thymocytes, since the proteasome is necessary for death in this
cell type (Grimm et al., 1996; Yang and Li, 2000). We found that RING
ubiquitin-ligase activity was indeed the primary determinant of XIAP;
however, the persistence of XIAP in dying thymocytes did not affect caspase
activation or enzymatic activity, and ΔRING cells died normally. These
results argue that the RING did not exert any appreciable pro-apoptotic
functions in dying thymocytes. Our results are more in line with data from
XIAP-null thymocytes, which die normally, than with thymocytes
overexpressing human XIAP, which are resistant to death (Conte et al.,
2001).

This highlights a discrepancy between different experimental

approaches used to study IAP function; heterologous expression systems
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may interfere with homeostatic mechanisms that control IAP levels, which
may introduce artifacts that confound the interpretation of results.
The proteasome is required for apoptosis in thymocytes, but the
identity of the labile (and presumably anti-apoptotic) factor(s) responsible
for this phenomenon remains elusive. Our results argue that XIAP is not
that factor. Another candidate is MCL-1, a short-lived anti-apoptotic BCL-2
family member that is degraded by the proteasome during apoptosis
following genotoxic stress (Nijhawan et al., 2003).

Although MCL-1

deficiency in lymphocytes results in increased apoptosis and profound
reductions in cell numbers, thymocyte development arrests at the doublenegative stage; thus, it is not yet possible to examine the role of MCL-1
degradation in the double-positive thymocyte population that is most
sensitive to apoptosis and makes up the bulk of the thymus (Opferman et al.,
2003).
Removing the RING domain rendered XIAP more susceptible to
caspase cleavage, and this accounted for almost all of the processing of
ΔRING XIAP that occurred during apoptosis. XIAP can homotrimerize
through its RING; trimerization allows Smac to derepress caspases more
efficiently in vitro (Gao et al., 2007); however, Smac was downregulated in
apoptotic ΔRING cells and caspase activity was unaltered in mutant
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thymocytes.

XIAP also binds cIAP1 through homotypic RING-RING

interactions (Silke et al., 2005) and XIAP is detected in high molecular
weight complexes in vivo (Bratton et al., 2001). It is not known if XIAP
forms higher order complexes in thymocytes, but the existing data argue that
a ΔRING mutant would be unable to oligomerize (Silke et al., 2002). In
principal, this could render XIAP more susceptible to proteolysis if steric
hindrance through oligomerization or ubiquitination normally excludes
caspases from IAP complexes. This is a plausible explanation because WT
XIAP was not cleaved by caspases during thymocyte apoptosis. We also
note that XIAP downregulation may depend on transubiquitination (e.g., by
the cIAP1 RING) instead of autoubiquitination, since the ΔRING mutation
also eliminated the binding surface for cIAP1 (Silke et al., 2005). Our
mutant could not rule out this hypothesis, but it could be tested easily in
cIAP1-null thymocytes (Conte et al., 2006).
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4 ELEVATED ACTIVITY AND REDUCED
UBIQUITINATION OF CASPASE-3 IN Δ RING
EMBRYONIC CELLS
4.1 SUMMARY
We used embryonic fibroblasts and stem cells to study apoptosis
triggered through mitochondria. We found that absence of XIAP RING
function led to elevated effector caspase activity during apoptosis. Deletion
of the RING did not affect the activation steps that led to caspase-3
cleavage, however, suggesting that the RING acts on activated effector
caspases. Consistent with this notion, we found evidence that XIAP RING
can serve as a ubiquitin-ligase for caspase-3, because ubiquitination of
caspase-3 subunits was impaired in apoptotic fibroblasts in the absence of a
functional XIAP RING.
caspase activity.

This phenomenon may underlie the increased

In spite of elevated caspase activity and reduced

ubiquitination, cells tolerated higher caspase activity without any increased
apoptosis.

Taken together, our findings show that XIAP can regulate

caspases through ubiquitination, in addition to direct binding and inhibition.
4.2 INTRODUCTION
This chapter describes experiments designed to investigate the
function of XIAP ubiquitin-ligase activity in embryonic cells, with an
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emphasis on stimuli that use factors associated with mitochondria as the
major means for activating apoptosis.

The mitochondrial pathway to

apoptosis is well characterized in mouse embryonic fibroblasts (MEFs) and
embryonic stem (ES) cells, largely because of gene targeting efforts to
inactivate major components of the pathway.

Genotoxic agents are

stereotypical activators of the mitochondrial pathway. Examples include
etoposide, which inhibits topoisomerase II to promote DNA strand breaks,
and UVC irradiation, which causes pyrimidine dimers and photoadducts.
Following genotoxic damage, p53 transduces apoptotic signaling by
transcriptionally activating BH3-only genes PUMA (Nakano and Vousden,
2001) and NOXA (Oda et al., 2000). While MEFs deficient for either gene
are refractory to apoptosis caused by genotoxic agents, PUMA deficiency
offers the greatest protection against the widest range of apoptotic stimuli
(Villunger et al., 2003). PUMA is upstream of BAX and BAK, because cells
lacking BAX and BAK together are insensitive to DNA-damage induced
apoptosis (Wei et al., 2001).

XIAP can inhibit apoptosis caused by

genotoxic agents by antagonizing caspase-3 when it is overexpressed
(LaCasse et al., 1998). We used mouse ES cells and MEFs to test how
XIAP RING deletion affects the response to stimuli that depend largely on
factors associated with mitochondria to activate apoptosis.
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4.3 EXPERIMENTAL PROCEDURES
4.3.1 Embryonic stem cell culture
The Neo cassette was removed from the hemizygous ΔRING (Neo)
embryonic stem (ES) cell line #125 by expressing the FLPe recombinase
(pCAGGS-FLPe, a gift from Chingwen Yang) transiently using the mouse
ES cell Nucleofection kit (program A-23; Amaxa). Nucleofected ES cells
were seeded on mitotically arrested embryonic fibroblasts and colonies were
allowed to grow for four days. ΔRING (ΔNeo) clones were identified by
screening replica-plated colonies by Southern blotting of ApaLI digested
genomic DNA using the same probe described in Chapter 2. Excision of the
Neo cassette was verified by direct sequencing, as described in Chapter I. A

ΔRING (ΔNeo) clone and the isogenic wild-type E14 parental line used for
gene targeting were cultured on gelatinized dishes without feeder layers in
ES cell medium (DMEM with 15% ES-qualified FBS [Chemicon], 100
U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-Glutamine, 100 mM
non-essential amino acids, 25 µM β-mercaptoethanol) with 10 ng/mL
leukemia inhibitory factor (Chemicon). Mitotically arrested fibroblasts were
essentially absent from the culture after serially passaging ES cells three
times in 1:10 splits. There was no need to re-target the XIAP locus because
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the E14 ES cell line used for gene targeting had an XY karyotype and hence
was hemizygous with respect to XIAP.
4.3.2 Isolation and culture of mouse embryonic fibroblasts
Primary MEFs were isolated from embryos 12.5 days after timed
matings; the presence of a copulation plug denoted day 0.5. Livers and
extraembryonic tissues were dissected away from the embryos, and heads
were reserved for genotyping. Embryos were passed twice through 18G
needles and once through 21G needles before plating on 10-cm dishes.
Primary MEFs were used through the fifth passage. Polyclonal pools of
transformed fibroblasts were obtained by infecting primary MEFs with a
bicistronic pBabe RasV12/E1A vector (gift from Joe Rodriguez) packaged
into an ecotropic Phoenix retrovirus. Primary and transformed MEFs were
cultured in MEF medium (DMEM with 15% FBS [Hyclone], 100 U/mL
penicillin, 100 µg/mL streptomycin, 2 mM L-Glutamine, 100 mM nonessential amino acids, 25 µM β-mercaptoethanol).
4.3.3 Induction of apoptosis in embryonic cells
ES cells were treated in culture with 100 µM etoposide or 1 µM
staurosporine for 10 hours, or left untreated in fresh medium.

Primary

MEFs were treated with 120 mJ/cm2 UVC (Spectrolinker XL-1500;
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Spectronics Corporation) or mock-irradiated by placing cells in the irradiator
without UVC light. Transformed MEFs were treated with 100 µM etoposide
or 60 mJ/cm2 UVC for 5 hours, or left untreated in fresh medium.
4.3.4 Apoptosis assays (indirect immunofluorescence)
Trypsinized single cell ES and MEF suspensions were collected with
any detached dead cells, washed twice in 0.5% BSA/PBS (pH 7.5), and
fixed in 2% paraformaldehyde in PBS for 10 minutes at 37 C. Cells were
washed twice and permeabilized in 90% methanol on ice for 30 minutes,
before washing twice more. Cells were blocked in 0.5% BSA/PBS for 10
minutes at room temperature before incubating with cleaved caspase
antibodies (caspase-3: Cell Signaling 9661, 1:200 dilution; caspase-8: Cell
Signaling 18C8, 1:50 dilution) for one hour at room temperature.
Antibodies were detected using FITC-conjugated secondary antibodies and
analyzed by flow cytometry. TUNEL and DEVDase assays were performed
as described in Chapter 3.
4.3.5 Analysis of caspase-3 ubiquitination state
Two 90% confluent 10-cm plates of MEFs were irradiated with 120
mJ/cm2 UVC or mock-irradiated, then harvested after 7 hours; 20 µM MG132 was added to cells 30 minutes before collection. Cell pellets were lysed
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in hot 1% (w/v) SDS to dissociate protein/protein interactions, then diluted
ten-fold in 1% Triton-X100 lysis buffer described in Chapter 3. Lysates
were clarified by centrifugation and normalized for total protein content
before rotating overnight at 4 C with a caspase-3 antibody (p32/p17, Cell
Signaling 8G10 rabbit monoclonal, 1:100).

Immunocomplexes were

collected with 25 µL of pre-washed protein A-magnetic beads (New
England Biolabs) by rotating for 2 hours at 4 C. Beads were collected using
a magnetic tube rock, washed three times in cold PBS and eluted in SDSPAGE sample buffer (New England Biolabs) for 5 minutes at 95 C before
immunoblotting.
4.4 RESULTS
4.4.1 Expression of XIAP ΔRING in ES cells
We investigated the expression of the XIAP ΔRING protein in
hemizygous ES cells. We obtained a XIAP ΔRING (ΔNeo) ES cell line by
transiently expressing the FLPe recombinase to delete the Neo cassette.
After screening 96 individual colonies, we found most of the colonies
showed clonal excisions of Neo (Figure 4.1A). Immunoblotting confirmed
that the XIAP ΔRING (ΔNeo) allele encoded a truncated protein of the
expected size in ES cells (Figure
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Figure 4.1 Excision of Neo cassette from Δ RING ES cells. (A) Southern
blot of ApaLI-digested DNA from individual ΔRING ES colonies after FLPe
expression. *, mixed Neo/ΔNeo colony; **, unexcised Neo colony. (B)
Immunoblot of ΔRING (ΔNeo) ES clone and isogenic WT line. (C)
Expression of ΔRING XIAP prior to deleting Neo.
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4.1B). The steady state expression level was comparable to that of the fulllength protein in isogenic WT cells. Thus, removing the RING did not
influence basal expression of XIAP in ES cells, while ΔRING XIAP is
expressed at higher basal levels in thymocytes (Figure 3.1). The expression
of ΔRING XIAP was lower with Neo still present in the final intron (Figure
4.1C). This finding stresses the importance of using a removable positive
selection cassette in gene targeting.
4.4.2 Elevated caspase-3 activity in cultured ΔRING embryonic cells
during apoptosis
We investigated how ES cells and primary MEFs responded to
different apoptotic stimuli that involve mitochondrial factors.

The

mitochondrial pathway of apoptosis functions primarily through caspase-9
and effector caspases-3 and -7, all of which can be inhibited by XIAP in
vitro. Caspase-3 enzyme activity was significantly elevated in ΔRING ES
cells treated with staurosporine or etoposide (Figure 4.2A, left) and in MEFs
irradiated with UVC (Figure 4.2A, right). This result was obtained from
bulk cellular lysates, so it does not offer any insights into caspase activity or
activation in individual cells. For this reason, we used an antibody against a
neoepitope exposed on the large subunit of cleaved, active caspase-3 to
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Figure 4.2 Elevated caspase activity but normal apoptosis in Δ RING
embryonic cells. (A) Caspase-3-like enzyme activity in bulk populations of
WT and ΔRING ES cells treated for 10 hours with etoposide or staurosporine
(left) and MEFs irradiated with UVC after 8 hours (right). (B) Percentages
of cells with active caspase-3 detected by indirect immunofluorescence. (C)
Apoptosis measured by the TUNEL assay. (*) P < 0.05; (**) P < 0.01,
paired two-tailed Student’s t-test.
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count the number of apoptotic cells by indirect immunofluorescence and
determined whether the increased caspase activity was due to a higher rate
of death for the ΔRING cells. We found equal numbers of WT and ΔRING
cells harboring active caspase-3 at times when caspase activity was greater
in ΔRING cells (Figure 4.2B). This result suggests that the steps that lead to
caspase-3 cleavage and activation were not accelerated in embryonic ΔRING
cells exposed to different stimuli that activated the mitochondrial pathway of
apoptosis. Likewise, cells of both genotypes died similarly, as assessed by
TUNEL (Figure 4.2B).
In spite of elevated caspase-3 enzyme activity in ΔRING cells, the
native and cleaved forms of different caspases were expressed similarly in
untreated and apoptotic ES cells (Figure 4.3A) and primary MEFs (Figure
4.3B). XIAP, cIAP1 and Smac/DIABLO became labile during thymocyte
apoptosis, but the expression levels of these proteins did not change
appreciably during ES cell apoptosis (Figure 4.3A).
4.4.3 Impaired caspase-3 subunit ubiquitination in irradiated ΔRING
fibroblasts
We asked if genetic deletion of the RING affected caspase-3
ubiquitination in apoptotic cells, because XIAP can polyubiquitinate
caspase-3 when it is overexpressed (Suzuki et al., 2001). Additionally, the
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Figure 4.3 MEF and ES cell immunoblots. (A) ES cells were treated for
the indicated time (hours) with staurosporine and immunoblotted as
indicated. (B) MEFs were irradiated with UVC and immunoblotted as
indicated.
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DIAP1 RING has an essential function in ubiquitinating the caspase-9
ortholog DRONC in Drosophila (Wilson et al., 2002). We used an antibody
that recognizes both full-length caspase-3 and the cleaved large subunit to
immunoprecipitate the caspase from mock- and UVC-irradiated cells, then
we immunoblotted with either an antibody against ubiquitin (Figure 4.4A,
left), or the large subunit of caspase-3 (Figure 4.4A, right). Both antibodies
detected a smear that typically indicates polyubiquitination when caspase-3
was immunoprecipitated from irradiated WT MEFs. This smear was largely
absent in irradiated ΔRING MEFs and in mock-irradiated WT and ΔRING
cells. These observations suggest that caspase-3 ubiquitination depends on
both apoptosis and the presence of an intact RING.
We also measured the chymotrypsin-like activity of the proteasome in
MEFs. Proteasome functions were comparable in WT and ΔRING MEFs
both with and without UVC treatment (Figure 4.4B).

The decrease in

activity is consistent with caspase-mediated inactivation of the proteasome
during apoptosis (Sun et al., 2004). The observed activity reflected genuine
proteasome activity because lactacystin, a highly specific small-molecular
inhibitor of the proteasome, abolished the signal (Figure 4.4B).
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Figure 4.4 Impaired caspase-3 ubiquitination during apoptosis in
ΔRING MEFs. (A) Caspase-3 was immunoprecipitated from MEFs 7h after
UVC or mock irradiation and immunoblotted with ubiquitin (left) or active
caspase-3 antibody (right). Cells were treated with 20 µM MG-132 for the
last 30 minutes. (B) Chymotrypsin-like activity of the proteasome after 7h
UVC treatment with and without lactacystin.
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Figure 4.5 Apoptosis in Ras/E1A-transformed MEFs. (A) Ras/E1A
MEFs were treated with etoposide or left untreated for 5 hours before
assaying DEVDase assay in bulk. Ras/E1A MEFs were treated with
etoposide, UVC irradiation, or left untreated for 5 hours before assaying
caspase-3 activation by indirect immunofluorescence (B) and TUNEL (C).
(*): P < 0.05, by paired two-tailed Student’s t-test.
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4.4.4 Apoptosis in oncogenically transformed MEFs
MEFs are primed to undergo apoptosis following oncogenic
transformation (Harrington et al., 1994; White, 2001).

We generated

polyclonal pools of transformed WT and ΔRING MEFs by retroviral
transduction of RasV12 and E1A to see if the transformed state might
sensitize ΔRING MEFs to apoptosis.

Different stimuli that impinge on

mitochondria caused elevated caspase activity in transformed ΔRING cells
without increasing apoptosis, albeit at lower drug concentrations and earlier
times than with primary cells (Figure 4.5). Similar to primary MEFs, the
transformed MEFs did not show any enhanced apoptosis in the absence of
the XIAP RING. Intriguingly, spontaneous apoptosis in the culture medium
was subtly elevated in untreated, transformed ΔRING cells.
4.5 DISCUSSION
This chapter describes genetic evidence for a role of XIAP ubiquitinligase activity in regulating caspase activity in ΔRING MEFs and ES cells.
Genetic deletion of the XIAP RING domain increased caspase-3 activity in
response to stimuli that activate apoptosis principally through factors
associated with mitochondria.

Removing XIAP RING function did not

affect caspase-3 activation, however. This argues that the domain did not
105

play a significant upstream role in inhibiting caspase-9, the major activator
of caspase-3 in MEFs. Surprisingly, MEFs and ES cells could tolerate
higher effector caspase activity without any increased death.
The RING appears to exert its effects on caspase-3 once the caspase
becomes activated. Indeed, we observed defective caspase-3 ubiquitination
in apoptotic ΔRING cells. This is in line with a prior report showing a role
for XIAP RING directed ubiquitination of caspase-3 (Suzuki et al., 2001).
Defective caspase ubiquitination likely explains the increased caspase
activity seen during apoptosis in ΔRING cells. It is surprising that the
expression of the subunits was not elevated appreciably, because
polyubiquitination generally leads to degradation by the proteasome.
Additionally, genetic inactivation of the Drosophila DIAP1 RING leads to
increased DRONC immunostaining that probably reflects increased protein
expression.

There are some precedents for this unexpected finding,

however, especially with regard to caspase ubiquitination. For example,
polyubiquitinated DRONC persists and is not degraded in cultured
Drosophila cells in one account (Wilson et al., 2002). The proteasome itself
is inactivated during apoptosis activated through the mitochondrial pathway.
Caspases can cleave key subunits of the 19S regulatory complex that
recognizes ubiquitinated substrates, thus inactivating the proteasome and
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leading to an accumulation of polyubiquitinated proteins during apoptosis
(Sun et al., 2004). To test this possibility in our system, we measured the
chymotrypsin-like activity of the proteasome in UVC-irradiated MEFs and
found that proteasome activity did indeed decrease during apoptosis,
although it was not abolished completely (Figure 4.4B). The formation of a
K48-linked polyubiquitination chain is a potent signal for the proteasome in
most cases, but it is possible that XIAP can assemble polyubiquitination
linkages with different topologies. The polyubiquitination chain assembled
on the large subunit of caspase-3 awaits a more thorough analysis, perhaps
by a direct determination of the ubiquitin linkages through massspectrometry.

In principal, the polyubiquitin chain assembled on active

caspase-3 could impair its ability to form product dimers through steric
hindrance. This may explain the lower activity of the caspase in cells that
retain XIAP E3 ubiquitin-ligase activity. Collectively, the experiments with
irradiated fibroblasts imply that deletion of the RING elevated caspase
activity without strongly affecting the levels of activated caspases, probably
by interfering with RING-directed ubiquitination that occurs on active
caspase-3 in normal apoptotic cells.
Comparisons between apoptotic thymocytes and embryonic cells
reveal some distinctions in XIAP RING functions between these two cell
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types. It is likely that the targets of the XIAP E3-ubiquitin ligase are distinct
between these cell types: XIAP becomes labile during thymocyte apoptosis
while caspases are unaffected by a RING deletion (Figure 3.1), while XIAP
is quite stable and caspases become targets for ubiquitination during the
death of embryonic cells (Figures 4.3, 4.4A). The molecular basis for this
distinction remains unclear. The proteasome has an uncommonly prominent
role in enabling apoptosis in thymocytes (Grimm et al., 1996). Perhaps the
heightened importance of the proteasome in this cell type enhances the
natural tendency of RING-containing IAPs to turn over (Silke et al., 2005),
while the enhanced stability of IAPs in embryonic cells allows them to
persist and participate in caspase ubiquitination.
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5 ΔRING FIBROBLASTS ARE SENSITIZED TO TNF-α
APOPTOSIS
5.1 SUMMARY
This chapter describes a novel role for XIAP as a negative regulator of
TNF-α-dependent apoptosis.

The elevated caspase-3 activity in ΔRING

cells treated with TNF-α in the absence of NF-κB survival signaling recalled
the results from Chapter 4, which described similar findings during
apoptosis through mitochondrial stimuli. Unlike mitochondrial apoptosis,
however, apoptosis was genuinely accelerated in ΔRING MEFs during TNFα−dependent apoptosis because we observed faster assembly of the
cytoplasmic complex that activates caspases and initiates apoptosis.
Cleaved caspases-8 and -3 were detectable in more ΔRING cells over time,
and TUNEL revealed markedly elevated apoptosis.
observations in XIAP-null cells.

We made identical

The accelerated TNF-α-dependent

apoptosis occurred independently or downstream of the JNK signaling
pathway that is required for initiating apoptosis. We also obtained similar
data with transformed ΔRING MEFs undergoing TRAIL-dependent
apoptosis. Our genetic data implicate XIAP as a genuine negative regulator
of the apoptotic program initiated by members of the TNF-α superfamily of
cytokines.
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5.2 INTRODUCTION
5.2.1 JNK and NF-κB pathways are antagonistic during TNF-α signaling
The TNF-α cytokine mediates a wide array of functions, including cell
proliferation, inflammatory cytokine production, and programmed cell
death. In MEFs, hepatocytes and many other cell types, soluble TNF-α has
no cytotoxic effects after ligating its principal receptor, TNF-RI.

This

occurs because TNF-α signaling simultaneously activates nuclear factor
kappa-B (NF-κB) pathways and c-Jun-N-terminal kinase (JNK), and these
two pathways mutually antagonize each other (Bubici et al., 2004).
Knockout mice have provided most of the evidence that JNK and NF-κB
pathways act antagonistically during TNF-α signaling. Mice deficient for
key components of the NF-κB pathway die in midgestation because of
massive liver apoptosis; this phenotype is rescued by genetic deletion of
TNF-α or its cognate receptor, TNF-R1 (Karin and Lin, 2002). Additionally,
knockout studies show that the JNK1 isoform is necessary for TNF-αdependent apoptosis (Liu et al., 2004).

Much of the TNF-α signaling

pathway remains unclear, however, and it is still unknown how signaling
through both JNK and NF-κB is modulated to promote cell survival or death
in different cell types.
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The principal role for NF-κB signaling in cells such as MEFs and
hepatocytes treated with TNF-α appears to involve transcriptional activation
of factors that actively antagonize the JNK pathway. MEFs lacking either
the IκB kinase β (IKKβ), an essential activator of the NF-κB pathway, or
RelA, a major NF-κB transcription factor, show sustained JNK activity by
TNF-α (Tang et al., 2001). This phenomenon has a functional consequence:
cells lacking either gene die in response to TNF-α alone, whereas WT cells
remain viable. RelA-deficient MEFs provide additional evidence that JNK
signaling has pro-apoptotic functions. A dominant-negative form of JNK
kinase (JNKK) prevents JNK activity and inhibits cell death, while a
constitutively active JNKK-JNK fusion protein promotes cell death with a
strong apoptotic component (Tang et al., 2001).
The NF-κB family transcribes a wide range of anti-apoptotic genes
after TNF-α treatment, including XIAP, cIAP1, BCL-2, BCL-XL, and c-FLIPL
(Tang et al., 2001).

It is currently unclear which factors are the most

important antagonists of JNK apoptotic signaling in MEFs treated with
TNF-α. Intriguingly, XIAP is the only known NF-κB target that can inhibit
both JNK signaling and apoptosis when overexpressed (Tang et al., 2001),
although JNK activation is normal in XIAP-null cells (Harlin et al., 2001).
The precise mechanism how JNK promotes apoptosis is still unclear, but one
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candidate molecule in the pathway is the E3 ubiquitin-ligase, Itch (Chang et
al., 2006). JNK phosphorylates and activates Itch, which in turn directs the
assembly of a polyubiquitin chain on c-FLIPL that leads to its degradation by
the proteasome. This facilitates cell death because c-FLIPL is a NF-κB
survival target that interferes with caspase-8 activation and prevents the
initiation of the TNF-α-dependent cell death program (Irmler et al., 1997).
5.2.2 TNF-α-dependent apoptosis requires sequential complexes
TNF-α triggers apoptosis in MEFs only when the NF-κB pathway is
inhibited by blocking global protein synthesis (e.g., with cycloheximide) or
by inactivating specific components of the pathway (Beg and Baltimore,
1996).

TNF-α-dependent apoptosis proceeds through two sequential

signaling complexes (Micheau and Tschopp, 2003). The first, “Complex I”,
is assembled proximal to the cell membrane immediately after receptor
ligation.

Complex I consists of the receptor, TNFR-1; the receptor

interacting protein 1 (RIP1) kinase; the TNFR-associated death domain
(TRADD) adaptor protein; and the TNFR-associated factor 2 (TRAF2), a
RING ubiquitin-ligase. TRAF2 assembles a K63-linked ubiquitin chain on
RIP1, which in turn recruits IKK to initiate NF-κB signaling. Intriguingly,
cIAP1 is efficiently recruited to Complex I only when NF-κB signaling is
intact.

TNFR-1, RIP, and TRADD undergo complex post-translational
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modifications in Complex I that include ubiquitination (Micheau and
Tschopp, 2003).

Caspase-8 and the FADD adaptor protein are

conspicuously absent from Complex I regardless of NF-κB status (Micheau
and Tschopp, 2003). In contrast, these proteins are immediately detected in
complex with the Fas receptor when cells are treated with agonistic Fas
antibody (Kischkel et al., 1995).

This finding highlights the added

complexity of TNF-α-dependent apoptosis.
A second complex, Complex II, is detectable in the cytoplasm starting
several hours after Complex I forms at the membrane (Micheau and
Tschopp, 2003). In the absence of NF-κB signaling, Complex II contains
TRADD, RIP1, caspase-8, and FADD, and c-FLIP. Recruitment of TRADD
and RIP1 to Complex II coincides with their dissociation from Complex I,
while caspase-8 recruitment requires homotypic DED-DED interactions with
FADD. Complex II is the activating platform for caspase-8; its assembly
leads to caspase-8 cleavage and apoptosis. When NF-κB signaling is intact,
however, Complex II contains much greater levels of c-FLIPL because cFLIPL is a transcriptional target of NF-κB.

The presence of c-FLIPL

antagonizes caspase-8 activation to promote cell survival (Micheau and
Tschopp, 2003). In fact, the levels of c-FLIP seem to determine if caspase-8
is activated during TNF-α signaling: downregulating c-FLIP through the
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ubiquitin system (Chang et al., 2006), or by preventing its synthesis (Kreuz
et al., 2001), correlates tightly with caspase activation.

Additionally,

knockdown of c-FLIP by short interfering RNAs (siRNAs) substitutes for
cycloheximide in promoting apoptosis through TNF-α (Wang et al., 2008).
5.2.3 Involvement of IAPs in TNF-α apoptosis
Recent studies using small-molecule IAP antagonists have revealed
IAPs to be central negative regulators of TNF-α-dependent apoptosis. Even
though IAP antagonists were designed using structural studies of the
Smac/XIAP-BIR3 interaction, IAP antagonists also bind other IAPs with
high affinity (Vucic and Fairbrother, 2007). IAP antagonists can displace
caspase-3 from XIAP (Li et al., 2004), promote cIAP1/2 autoubiquitination
and degradation by the proteasome (Varfolomeev et al., 2007; Vince et al.,
2007), while probably exerting other effects. IAP antagonists synergize with
TNF-α and a related death ligand, TRAIL (TNF-related apoptosis inducing
ligand) to induce apoptosis in a variety of cancer cell lines, while exerting no
cytotoxic effects in primary skin fibroblasts

(Li et al., 2004).

Downregulation of cIAP1/2 by IAP antagonists can initiate apoptosis in an
NF-κB-dependent manner by transcriptionally upregulating TNF-α, which
then appears to kill cells in an autocrine fashion (Petersen et al., 2007;
Varfolomeev et al., 2007; Vince et al., 2007).
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Upregulation of TNF-α

occurs in part through a non-canonical (e.g., RIP1-independent) NF-κB
pathway that is dependent on NIK1 (NF-κB-interacting kinase) as an
upstream activator. NIK1 is usually undetectable in cells because cIAP1/2
RING-dependent ubiquitination targets it for degradation in the proteasome;
however, depletion of cIAP1/2 by IAP antagonists stabilizes NIK to activate
NF-κB signaling (Varfolomeev et al., 2007; Vince et al., 2007).
This model of IAP antagonist activity invokes a pro-apoptotic role for
NF-κB in upregulating TNF-α, which is surprising because NF-κB has prosurvival functions in virtually every other context. A novel mechanism for
activating caspase-8 during TNF-α-dependent apoptosis was uncovered
recently by studying IAP antagonists.

Depleting cIAP1/2 by IAP

antagonists (or siRNA silencing) liberates RIP1 from Complex I, allowing it
to form a new complex in the cytosol with FADD that promotes caspase-8
activation.

This complex is distinct from Complex II because it is not

inhibited by c-FLIP; instead, cIAP1/2 control its formation.
5.2.4 Pro-apoptotic role of cIAP1 RING in signaling through TNF-R2
The cIAP1 RING has a pro-apoptotic role in the TNF-α-dependent
apoptotic program signalled through TNF-RII, the second major TNF
receptor (Li et al., 2002). Unlike ubiquitous TNF-R1, expression of TNFRII is restricted to certain cell types including myeloid cells, T- and B-cells.
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Ligation of TNF-RII potentiates pro-apoptotic signaling through TNF-R1,
although it does not appear to directly activate caspase-8 (Zheng et al.,
1995). TNF-RII lacks death domains that can recruit TRADD; instead, it
binds TRAF2 directly to initiate signaling. TRAF2 protects cells from TNFα-dependent apoptosis at least in part by activating NF-κB survival
signaling, and TRAF2-null animals die from rampant TNF-α-dependent
apoptosis (Yeh et al., 1997).

Specifically ligating the TNF-RII recruits

TRAF2 and cIAP1/2 to the receptor, leading to downregulation of TRAF2.
This occurs because the cIAP1 RING is a ubiquitin-ligase that assembles a
polyubiquitin chain on TRAF2 that marks it for degradation by the
proteasome (Li et al., 2002). cIAP1 RING mutants function as dominantnegative proteins that prevent TRAF2 downregulation and delay TNF-α
apoptosis. The cIAP1 RING also targets ASK1, a MAPK kinase kinase in
the JNK pathway, for polyubiquitination and degradation (Zhao et al., 2007).
Normally, ASK1 degradation would attenuate JNK signaling during TNF-α
signaling; however, cIAP1-null B-cells show stabilized ASK1 after TNFR-II
ligation and persistent JNK signaling (Zhao et al., 2007). It is unclear if this
phenomenon has a pro-apoptotic consequence. Thus, IAP RINGs can act
pro-apoptotically in some circumstances, by targeting anti-apoptotic
molecules such as TRAF2 for degradation.
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5.3 EXPERIMENTAL PROCEDURES
5.3.1 Induction of death receptor apoptosis
Primary MEFs were treated with 100 ng/mL recombinant murine
TNF-α (Peprotech) and 1 µg/mL cycloheximide (“CHX”, Sigma).
Transformed MEFs were treated with 100 ng/mL TNF-α with and without 1
µg/mL CHX for 3 hours, or 50 ng/mL recombinant murine “SuperKiller”
TRAIL (Alexis) for 10 hours.
5.3.2 Immunoprecipitation of the caspase-8 activating complex
To immunoprecipitate caspase-8 complexes, primary MEFs were
treated with TNF-α/CHX and harvested by scraping detached and adherent
cells from two 10-cm plates per treatment. Cell lysates were prepared in
lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 0.2% Nonidet P40, 10%
glycerol) supplemented with protease inhibitors, and then snap-frozen in
liquid nitrogen.

Lysates were thawed in ice water, clarified by

centrifugation and normalized for total protein content (600 µg per sample)
before incubating overnight with a FADD (Santa Cruz M-19 goat
polyclonal, 2 µg) or RIP1 (BD Biosciences, 1:100 dilution) antibody.
Immunocomplexes were collected as described in Chapter 4, except using
protein G-magnetic beads (New England Biolabs).
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5.3.3 Stable knockdown of RelA by shRNA
Ras/E1A-transformed MEFs were transduced with knockdown
retroviruses (pMLP-empty or pMLP-RelA-shRNA; GFP produced by IRES)
produced by the Phoenix ecotropic packaging line. Transduced cells were
collected by sorting GFP-positive cells. Transduced cells were seeded in 60mm plates and treated with 100 ng/mL TNF-α alone for 3 hours, before
assaying DEVDase activity.
5.3.4 Rescue experiment
Primary MEFs were transduced with retroviruses produced by
packaging pBabe Puro N-myc XIAP WT, XIAP ΔRING, or empty vector in
the Phoenix ecotropic packaging line. After 24 hours, transduced cells were
selected in 1 µg/mL puromycin for three days. Cells were treated with TNFα/CHX for 8 hours and assayed for caspase-3 activity as described above.
5.3.5 Transient JNK assay
Primary MEFs were seeded in 6-well plates and treated with 100
ng/mL TNF-α alone.

Cells were collected by scraping directly into

microcentrifuge tubes, which were flash frozen in liquid nitrogen and used
for immunoblotting as described above.
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5.3.6 NF-κB luciferase assay
WT and ΔRING MEFs were transiently transfected with the pNF-κB
Luc reporter plasmid (Clontech) using the Nucleofector MEF Kit 2 (Amaxa;
program A-23). 24 hours later, MEFs were treated for 4 hours with 100
ng/mL TNF-α; 100 ng/mL TNF-α and 1 µg/mL CHX; or left untreated in
fresh medium. Cells were harvested and lysed in DEVDase lysis buffer as
described above. Cell lysates (30 µg/30 µL) were incubated with equal
volumes of luciferase substrate solution (Stratagene), before measuring
luciferase activity in a plate reader set to luminometer mode.
5.4 RESULTS
5.4.1 Deletion of XIAP RING sensitizes primary MEFs to TNF-α apoptosis
We treated WT and ΔRING MEFs with TNF-α and cycloheximide
(CHX) to activate death receptor apoptosis, and found mutant cells to be
much more responsive to death. This was evident by the increased number
of cells with apoptotic morphology, or that had detached from the dish
(Figure 5.1). Additionally, we found significantly elevated caspase-3 activity
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Figure 5.1 Sensitivity to TNF-α-dependent death in Δ RING MEFs.
Brightfield micrographs of WT and ΔRING MEFs treated with TNF-α/CHX
for the indicated times.
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Figure 5.2 TNF-α-dependent apoptosis was accelerated in ΔRING
MEFs. (A) Caspase-3-like enzyme activity in bulk cellular lysates after 8h
TNF-α/CHX treatment. (B) Percentages of cells with cleaved caspase-8 as
determined by indirect immunofluorescence over time. (C) Caspase-3
activation measured by indirect immunofluorescence. (D) Apoptosis
measured by TUNEL staining. (*): P < 0.05; (**): P < 0.01, by two-tailed
paired Student’s t-test.
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in ΔRING cells (Figure 5.2A).

This result recalled the greater caspase

activity described in Chapter 3, when apoptosis was triggered by stimuli
with a strong mitochondrial signaling component. Unlike mitochondrial
apoptosis, however, treatment with TNF-α/CHX accelerated different
markers of apoptosis in ΔRING MEFs. Cleaved initiator caspase-8 was
detected by indirect immunofluorescence in greater percentages of ΔRING
cells over time (Figure 5.2B).

Caspase-3 activation was accelerated, as

evidenced by the increased number of cells stained by the CM1 antibody
that recognizes the cleaved large subunit of caspase-3 (Figure 5.2C).
Finally, TUNEL revealed that ΔRING MEFs had undergone more apoptosis
(Figure 5.2D).
It is unclear if caspase-8 must undergo intrachain proteolysis before it
can cleave and activate caspase-3 during death receptor apoptosis. To verify
that the enhanced cleavage of caspase-8 detected by immunofluorescence
reflected genuinely accelerated activation, we decided to immunoprecipitate
the cytoplasmic complex (Complex II) that recruits and activates caspase-8
after TNF-α/CHX treatment (Micheau and Tschopp, 2003).

We used

FADD, a requisite cofactor for caspase-8 activation in this cell type, to
immunoprecipitate the complex to study recruitment of key components
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Figure 5.3 Faster assembly of caspase-8 activating complex in ΔRING
MEFs. WT and ΔRING MEFs were treated with TNF-α/CHX for the
indicated times, and the assembly of the complex that activates caspase-8
was studied by coimmunoprecipitation using a FADD (A) or RIP1 antibody
(B). The native form of cIAP1 is indicated by an arrowhead.
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because it is unique to Complex II. Both full-length and cleaved caspase-8
were readily detected in complex with FADD after 4 hours in ΔRING cells;
this was evident after 6 hours in WT cells upon longer exposure of the
immunoblot (Figure 5.3A). Likewise, a higher molecular weight form of
cIAP1 was recruited to the complex more quickly in ΔRING cells.
Intriguingly, this form of cIAP1 appeared with comparable kinetics in cells
of both genotypes (Figures 3.1A; 5.7), but was recruited more quickly to the
caspase-8 activating complex in ΔRING cells. The short form of c-FLIP (cFLIPs) was bound at all times to FADD in cells of both genotypes.
Similarly, RIP1 pulled down greater amounts of cIAP1 in ΔRING MEFs
after TNF-α/CHX treatment (Figure 5.3B).

Taken together with the

immunofluorescence data, these results argue that the increased apoptosis in

ΔRING cells indeed reflected an accelerated activation of cell death
signaling pathways.
5.4.2 Transformed ΔRING MEFs are sensitized to TNF-α apoptosis after
RelA-knockdown
Inhibiting all translation with cycloheximide probably has farreaching effects in a cell beyond preventing the synthesis of pro-survival
NF-κB targets. To rule out off-target effects of CHX, we inactivated NF-κB
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specifically by stably expressing a short hairpin interfering RNA against
RelA, one of the principal members of the family of NF-κB transcription
factors. We used Ras/E1A-transformed MEFs for this experiment. RelA
knockdown mimicked CHX treatment, as evidenced by increased caspase-3
activity in ΔRING cells treated with TNF-α alone (Figure 5.4). This result
suggests that ΔRING functioned specifically in TNF-α−dependent apoptosis
and independently of any non-specific effects of CHX.
5.4.3 XIAP-null MEFs were also sensitized to TNF-α-dependent apoptosis
We reasoned that the hypersensitivity to TNF-α apoptosis would be
observed in XIAP-null fibroblasts if the XIAP RING were a true negative
regulator of apoptosis in this context. We isolated primary MEFs from a
mouse engineered to lack XIAP expression by homology-based elimination
of the first exon (Harlin et al., 2001). Immunoblotting verified the absence
of XIAP protein in these cells (Figure 5.5E). Treatment with TNF-α/CHX
revealed that the XIAP-null MEFs were as sensitized to apoptosis as cells
lacking the RING alone.

Caspase-3 enzyme activity increased (Figure

5.5A), cleaved caspases-8 and -3 were detected in more cells (Figure 5.5B,
C), and TUNEL revealed heightened apoptosis (Figure 5.5D). Thus, XIAP
was a genuine negative regulator of TNF-α-dependent on its RING domain.
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Figure 5.4 Greater TNF-α-dependent caspase-3 activity in Δ RING cells
lacking RelA. Caspase-3-like activity measured from Ras/E1A-transformed
MEFs expressing a shRNA against RelA and treated with TNF-α alone for 3
hours.
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Figure 5.5 Sensitivity to TNF-α apoptosis in XIAP-null MEFs. (A)
Caspase-3 activity measured in bulk lysates after 8h treatment with TNFα/CHX. (B) Caspase-8 cleavage as assayed by indirect immunofluorescence.
(C) Caspase-3 cleavage detected by indirect immunofluorescence. (D)
Apoptosis as measured by the TUNEL assay. (E) Immunoblots of MEFs
treated with TNF-α/CHX for the indicated times. (*): P < 0.05, two-tailed
paired Student’s t-test.
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5.4.4 The XIAP ΔRING mutation was not dominant in TNF-α apoptosis
We used retroviral transduction to complement ΔRING MEFs with a
full-length XIAP construct containing a functional RING domain, in an
attempt to rescue the apoptosis phenotype in these cells. Reintroducing fulllength XIAP to ΔRING cells reduced caspase-3 activity to the normal levels
seen in WT cells during apoptosis (Figure 5.6). Ectopic ΔRING XIAP did
not function as a dominant-negative inhibitor of the endogenous XIAP
RING, because WT cells did not show elevated caspase-3 activity when we
expressed a ΔRING construct. Ectopic expression of XIAP ΔRING also
lowered caspase-3 activity in ΔRING cells, although not to the same extent
as the XIAP WT construct. This may be explained by the greater abundance
of ectopic ΔRING protein compared to ectopic full-length protein. XIAP
has well-documented anti-apoptotic effects when overexpressed, and the
decreased caspase-3 activity in ΔRING-overexpressing, ΔRING MEFs may
reflect this phenomenon. The differences in expression may be an artifact
from using strong retroviral promoters, since WT and ΔRING proteins are
expressed at comparable basal levels when transcribed from the endogenous
XIAP promoter in MEFs (Figure 5.7).
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Figure 5.6 Rescue experiment. MEFs were retrovirally transduced with
the indicated vectors, then treated with TNF-α/CHX for 8 hours before
assaying caspase-3 activity.
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5.4.5 Normal expression of components of TNF-a apoptotic pathway
We investigated the expression levels and behaviors of key
downstream components of the TNF-α apoptotic program (Figure 5.7). The
principal TNF receptor in MEFs, TNF-R1, was expressed comparably in
cells of both genotypes. Other key cytoplasmic components of the receptor
complex were as well, including TRAF2, FADD, and c-FLIP (the large form
of which was degraded during apoptosis). RIP kinase plays a key role in
promoting NF-κB signaling and inhibiting apoptosis in TNF-α treated cells,
and it is inactivated by caspase-8 cleavage (Lin et al., 1999) and proteasomal
turnover (Wertz et al., 2004). The basal levels of RIP1 were similar in WT
and mutant cells, though it was completely cleaved in ΔRING MEFs at a
time (8h) when most of the cells were apoptotic. The XIAP RING functions
anti-apoptotically in primary hepatocytes treated with TGF-β by targeting
TAK1 (a MAPK kinase kinase in the JNK pathway) for degradation and
thereby attenuating apoptosis through the JNK pathway (Kaur et al., 2005).
We investigated the expression of this protein in ΔRING cells, since elevated
levels of TAK1 might sensitize cells to JNK activation and hence apoptosis
in the absence of NF-κB signaling. However, there was no difference in
TAK1 expression in the mutant cells (Figure 5.7). NIK was upregulated
similarly in WT and ΔRING cells. This seems to argue against any role for
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Figure 5.7 TNF-α apoptosis immunoblots. MEFs were treated with TNFa/CHX for the indicated times before immunoblotting with as specified.
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the ΔRING mutation in NIK-mediated upregulation of TNF-α and apoptosis
seen after IAP antagonist treatment (Varfolomeev et al., 2007; Vince et al.,
2007).
Both WT and ΔRING XIAP were cleaved during apoptosis, while
cIAP1 and the BIR-containing protein Survivin were downregulated
similarly in both genotypes (Figure 5.7). The expression of Smac/DIABLO
was unchanged between WT and ΔRING cells. Immunoblotting confirmed
the immunofluorescence data, by demonstrating enhanced caspase-3
cleavage that was evident after 4 hours of treatment with TNF-α/CHX.
Additionally, the expression of the native form of caspase-8 strongly
decreased after 8 hours in ΔRING cells (Figure 5.7). Anti-apoptotic BCL-XL
expression was elevated somewhat after 4 hours in ΔRING cells, but the
significance is unclear because apoptosis was already underway.
5.4.6 Normal JNK activation and NF-κB signaling in ΔRING MEFs
Since the key components that activate or inhibit JNK were similarly
expressed in WT and ΔRING MEFs, we predicted that JNK activation would
occur normally in ΔRING MEFs. Indeed, the activating phosphorylations of
different JNK isoforms appeared with identical kinetics in TNF-α/CHX
treated ΔRING MEFs (Figure 5.7). Surprisingly, this was evident at a time
132

(4h) when there were already differences in apoptosis between the two
genotypes. We also observed normal JNK phosphorylation in XIAP-null
cells (Figure 5.5E). The phosphorylation status of JNK is transient when the
NF-κB pathway is intact, and sustained in its absence (Tang et al., 2001).
This occurs because NF-κB signaling prevents the accumulation of reactive
oxygen species that would otherwise inactivate MAP kinase phosphatases
(Kamata et al., 2005). Treatment with TNF-α alone elicited transient JNK
phosphorylation in ΔRING MEFs that was indistinguishable from WT cells
(Figure 5.8A). This result implies that NF-κB signaling remained intact in
MEFs when the XIAP RING was genetically deleted, because transient JNK
phosphorylation is a readout for NF-κB function.
We also measured NF-κB activity in MEFs using a reporter plasmid
where the expression of luciferase was driven by optimal NF-κB responsive
elements. Treating MEFs with TNF-α alone provoked a strong increase in
the luciferase signal in cells of both genotypes, while TNF-α together with
CHX yielded essentially the same signal as no treatment at all (Figure 5.8B).
Taken together, these results suggest that there was no general propensity for

ΔRING cells to activate JNK, or maintain activated JNK. The mechanism
that promoted enhanced caspase activation in ΔRING and XIAP-null cells
probably acted independently or downstream from signals that activated
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Figure 5.8 NF-κB signaling appeared intact in Δ RING MEFs. (A) WT
and ΔRING MEFs were treated with TNF-α alone for the indicated times
before immunoblotting. (B) MEFs were transfected with a NF-κB luciferase
reporter 24 hours prior to assessing NF-κB activity 4 hours after treatment as
indicated.
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JNK. JNK activation is normal in TNF-α-treated MEFs from the XIAP-null
mouse (Harlin et al., 2001), and we have now shown these cells to be
sensitized to TNF-α apoptosis.
5.4.7 Transformed ΔRING MEFs were sensitized to TRAIL apoptosis
TRAIL is a member of the TNF-α superfamily of death receptor
ligands with potential therapeutic applications, because it can preferentially
trigger apoptosis in many transformed cell types while leaving normal cells
unharmed. The reasons behind this phenomenon are unclear, although there
are some clues. E1A, c-Myc and other factors that enforce cycling can
prime mitochondria to activate caspase-3 further, by shifting BAK into a
poised, activated state (Nieminen et al., 2007).

Furthermore, E1A

expression leads to transcriptional upregulation of caspases and thus
sensitizes fibroblasts to apoptosis (Nahle et al., 2002).

We used the

Ras/E1A-transformed MEFs described in Chapter 3 to test whether genetic
deletion of the XIAP RING can sensitize MEFs to TRAIL-mediated
apoptosis. Recombinant TRAIL alone elicited apoptosis in both WT and

ΔRING Ras/E1A MEFs, but ΔRING cells were significantly more
responsive. Bulk caspase-3 activity increased (Figure 5.9A), and caspases-8
and -3 were detected in greater percentages of ΔRING cells (Figure 5.9B, C).
Cell death was also elevated in mutant MEFs (Figure 5.9D). The data from
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Figure 5.9 Hypersensitivity to TRAIL in transformed Δ RING MEFs.
(A) Caspase-3 activity as measured in bulk. Indirect immunofluorescence
was used to count the number of cells with cleaved caspase-8 (B) and
caspase-3 (C). (D) Apoptosis as measured by TUNEL. Cells were treated as
described in Experimental Procedures. (*): P < 0.05; (**): P < 0.01, twotailed paired Student’s t-test.
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RING-mutant cells imply that the RING negatively regulates TRAIL
apoptosis, as well as TNF-α. Ras/E1A transformation also rendered MEFs
more susceptible to TNF-α/CHX apoptosis. The differences in caspase-3
activity were still apparent between WT and ΔRING cells, but they were
detectable at earlier times (Ras/E1A: 3 hours, primary: 8 hours).
Intriguingly, mutant cells also showed a subtle but significant increase in
caspase-3 activity in response to TNF-α alone. Similar observations were
made using immortalized cIAP1-null MEFs (Vince et al., 2007). These
results also accord with a genetic argument that that XIAP non-redundantly
inhibits TRAIL apoptosis in human colon cancer cells (Cummins et al.,
2004).
5.5 DISCUSSION
Our experiments with XIAP ΔRING and knockout cells implicate the
XIAP RING as a novel negative regulator of TNF-α-dependent apoptosis in
MEFs. This phenotype was not noted in the initial description of the XIAPnull mouse (Harlin et al., 2001). The published account describes normal
JNK activation and concludes that TNF-α apoptosis is unaltered in XIAPnull cells.

This finding is consistent with our observations, since the

activating phosphorylations on JNK occurred with normal kinetics in cells
137

from the published XIAP-null mouse (Figure 5.5) and the ΔRING mouse
(Figure 5.7). Furthermore, since loss of RING function mimics a complete
null allele in TNF-α-dependent apoptosis, the ΔRING mutation constitutes a
genuine loss-of-function.
We failed to identify any differentially expressed proteins in the TNFα effector pathways that would readily explain the sensitivity to TNF-α
apoptosis. All of the key players in the JNK pathway were present in equal
amounts in unstimulated MEFs of both genotypes, and the only differences
(e.g., RIP1 cleavage and TAK1 disappearance after 8h in ΔRING MEFs)
were evident at a time when most of the mutant cells were dead. Previous
work identified XIAP as a NF-κB target that specifically antagonized JNK
activity (Tang et al., 2001). This conclusion is based on overexpression
studies in MEFs. Although we did not do a JNK assay, the activation of
JNK by upstream kinases occurred normally, as assessed by immunoblotting
with a phosphorylation-specific antibody. Based on this result and other
published findings, we conclude that the sensitivity to TNF-α-dependent
apoptosis occurs downstream or independently of the signals that activate
JNK.
It is unclear if caspases can account for the hypersensitivity to TNF-α
apoptosis in XIAP loss-of-function MEFs.
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Caspase-3 ubiquitination is

probably impaired during TNF-α apoptosis, as we demonstrated with UVC
irradiation (Figure 4.4A). There is evidence that caspase-8 can be activated
by caspase-6 in a feedback mechanism (Murphy et al., 2004). This may
account for some of the accelerated apoptosis if XIAP RING normally
ubiquitinates and inhibits other effector caspases. It seems more likely that
the differences in apoptosis arise at a point proximal to the receptor, because
we noted that Complex II assembled more rapidly in ΔRING cells. It is also
possible that the effects are indirect. XIAP and cIAP1 can heterodimerize
through RING-RING interactions (Silke et al., 2005). If this interaction
were necessary for cIAP1 localization or anti-apoptotic functions, such as
those discussed in the chapter introduction, then removing the XIAP RING
may sensitize cells to TNF-α-dependent apoptosis indirectly.

However,

XIAP does not associate with the TNF-R1 complex, and attempts to
investigate the subcellular localization of endogenous cIAP1 in ΔRING cells
were stymied by the lack of a suitable antibody for immunofluorescence.
Perhaps this matter will be resolved as better tools are developed.
The sensitivity to death receptor apoptosis extended to TRAIL as
well, as demonstrated by the experiments with oncogenically transformed
MEFs in Figure 5.8. This is consistent with prior experiments showing that
deletion of the XIAP locus by homologous recombination sensitizes colon
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cancer cells to TRAIL (Cummins et al., 2004). Attempts to extend these
findings to Fas death receptor signaling were unsuccessful, probably because
Fas receptor is expressed at very low levels in fibroblasts. The susceptibility
to TNF-α or TRAIL apoptosis did not extend to an experimental model of
septic shock and liver failure triggered by systemic TNF-α administration
(Figure 2.4).

This difference may stem from the requirement for

mitochondrial amplification of death receptor signaling in hepatocytes (Yin
et al., 1999).

Perhaps the sensitizing effects of ΔRING XIAP are not

sufficient to overcome this threshold.
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6 LOSS OF XIAP RING FUNCTION IMPROVES
SURVIVAL IN THE Eµ-Myc LYMPHOMA MODEL
6.1 SUMMARY
This chapter describes how loss of RING function improves survival
in the Eµ-Myc model of non-Hodgkin’s lymphoma. ΔRING mice showed
significantly longer lymphoma-free survival and lessened incidence of
leukemia. There was a reduction in the number of large, proliferating B-cell
precursors in the bone marrow and in the periphery. RING inactivation led
to elevated apoptosis in the population of proliferating, pre-malignant Bcells in the bone marrow. Purified B-cells underwent apoptosis more readily
when cultured without serum.

The data strengthen the notion that the

ΔRING mutation is an XIAP loss-of-function and show a novel role for
RING function in tumorigenesis.
6.2 INTRODUCTION
6.2.1 The Eµ-Myc lymphoma model
The chromosomal translocations found in hematopoietic malignancies
have offered a wealth of insights into the signaling pathways misregulated in
human cancer.

Many common lymphomas and leukemias arise when

somatic B-cell receptor arrangement goes awry and juxtaposes enhancers in
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the receptor locus with potent oncogenes (Cory, 1986). The BCL-2 gene, for
example, was first cloned at the breakpoint of the t(14;18) translocation
found in follicular lymphoma, where its expression is harnessed to the IgH
locus (Tsujimoto et al., 1984). A t(8;14) translocation is commonly found in
Burkitt’s lymphoma in humans, and the analogous translocation t(12;15)
underlies experimentally induced plasmacytomas in BALB/c mice (Adams
et al., 1983). This translocation brings the Myc coding sequence under the
control of the µ intronic enhancer in the IgH locus. Since the IgH locus
encodes the heavy chain of the B-cell receptor, the Eµ-Myc translocation
leads to constitutive misexpression of Myc throughout the stages of B-cell
development where the B-cell receptor is expressed (typically, the pro-B
stage and onward) (Harris et al., 1988).
Transgenic mice expressing the Eµ-Myc fusion offer clear evidence
that this translocation can cause lymphoma and leukemia (Adams et al.,
1985). This mouse transgenically expresses an Eµ-Myc translocation cloned
from a murine plasmacytoma, and it represents a technological triumph
because it is one of the first transgenic mice ever created. Mice harboring
the Eµ-Myc translocation develop lymphoma and lymphoblastic leukemia,
but the neoplastic cells (principally, pre-B and B-cells) are distinct from the
cells that arise in Burkitt’s lymphoma, which affects mostly mature B-cells
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(Adams et al., 1985). Better models of Burkitt’s lymphoma have since been
developed (Kovalchuk et al., 2000), but the Eµ-Myc mouse remains a widely
used model of non-Hodgkin’s lymphoma.
Lymphocytes from Eµ-Myc mice progress through three distinct
stages (Sidman et al., 1993). Initially, B-cell precursors hyper-proliferate in
the bone marrow starting before birth (Langdon et al., 1986). The expanded
pool of lymphocytes is comprised principally of pre-B-cells, and some of
them migrate to the periphery (Sidman et al., 1993).

The leukocyte

population then returns to near-normal levels, probably because of apoptosis
in the bone marrow and periphery (Jacobsen et al., 1994). This occurs partly
because pre-malignant Eµ-Myc B-cells remain dependent on limiting
amounts of cytokines for survival signaling (Langdon et al., 1988). The
length of this intermediary period varies among individuals. The final stage
is marked by emergence of disseminated lymphoma and a pathological
elevation in the numbers of large, circulating lymphoblasts as the mice
develop leukemia (Sidman et al., 1993). Death usually ensues soon after.
Lymphoma latency varies among not only different mouse strains, but
also genetically identical mice from the same inbred strain (Sidman et al.,
1988). We can make several inferences from these observations. First,
genetic modifiers unique to different mouse strains synergize with Eµ-Myc
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to influence the latency of disease. Eµ-Myc mice on the C57BL/6 strain, for
example, live considerably longer than Eµ-Myc BALB/c mice (Sidman et
al., 1988). Additionally, the variable latency among inbred mice points to
the involvement of somatic, tumorigenic mutations that occur stochastically.
Indeed, cells from the pre-lymphoma stage in Eµ-Myc mice are not
malignant and do not survive transplantation into compatible hosts (Langdon
et al., 1986). Even cells from double transgenic Eµ-Myc/BCL-2 mice are not
transplantable at early stages, despite their markedly enhanced survival in
the absence of growth factors (Strasser et al., 1990). These findings imply
that three or more oncogenic “hits” may be required to transform
lymphocytes. Remarkably, the likelihood that a given Eµ-Myc pre-B cell
will become malignant is only about 1 in 1010 on a mixed genetic
background (Harris et al., 1988), and the tumors that do arise are invariably
of clonal origin (Adams et al., 1985; Harris et al., 1988).
6.2.2 Apoptosis as a critical modulator of Eµ-Myc lymphoma
There is a wealth of evidence implicating apoptosis as a key modulator
of lymphoma development in the Eµ-Myc mouse. The observation that
BCL-2 synergizes with Eµ-Myc to accelerate lymphoma by increasing the
survival of transgenic B-cells is a hallmark finding in the cell death field
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(Strasser et al., 1990; Vaux et al., 1988). Many other factors related to
apoptosis are now known to modulate the Eµ-Myc model. For instance, Bcells from Eµ-Myc mice undergo spontaneous p53-dependent apoptosis, and
there is strong selective pressure to inactivate the ARF-Mdm2-p53 axis
(Eischen et al., 1999) (Eischen et al., 2004; Schmitt et al., 1999). p53
deficiency reduces survival of Eµ-Myc mice (Schmitt et al., 1999), while
loss of Mdm2 prolongs survival by facilitating p53-dependent apoptosis of
pre-malignant cells (Alt et al., 2003). Expression of BCL-2 or dominantnegative caspase-9 phenocopies loss of p53 function in the Eµ-Myc model;
remarkably, expression of either genes relieves the selective pressure to
inactive the p53 locus in vivo (Schmitt et al., 2002). These findings imply
that p53’s chief tumor suppressor function in Eµ-Myc lymphoma is to
activate

apoptosis

through

mitochondrial

factors

and

caspase-9.

Furthermore, BIM appears to be the principal BH3-only factor that activates
apoptosis in the Eµ-Myc model (Egle et al., 2004).
6.2.3 XIAP in lymphoid malignancy
Overexpression of XIAP can inhibit cell death in virtually every cell
culture system (LaCasse et al., 1998), and elevated XIAP expression is
found in many human tumors (Hunter et al., 2007).
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Studies like these

implicate XIAP gain-of-function mutations in the development of cancer,
and led to the development of therapeutic compounds that antagonize IAPs
to promote apoptosis in human tumors (Vucic and Fairbrother, 2007). There
is little experimental evidence linking XIAP function to tumorigenesis,
however, and much of the data remains circumstantial. Although transgenic
mice overexpressing human XIAP in the thymus show increased numbers of
developing T-cells and resistance to apoptosis (Conte et al., 2001), no
published mouse models have shown that XIAP can promote tumor
formation.
A positional cloning effort identified XIAP deficiency as a genetic
basis for the human X-linked lymphoproliferative syndrome (Rigaud et al.,
2006). Lymphocytes in afflicted patients are sensitized to TRAIL and Fas
death receptor apoptosis and natural killer T-lymphocytes are depleted.
How enhanced apoptosis leads to lymphoproliferation remains a mystery.
This report provides the clearest link between XIAP loss-of-function and
human disease. The data described in this chapter extend these findings to
the Eµ-Myc mouse model of lymphoma, and provide genetic evidence
implicating RING function in inhibiting apoptosis in tumorigenesis.
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6.3 EXPERIMENTAL PROCEDURES
6.3.1 Eµ-Myc Mouse Experiments

ΔRING mice were backcrossed to C57BL/6 mice for at least six
generations before mating with C57BL/6 Eµ-Myc mice purchased from
Jackson Laboratory (strain B6.Cg-Tg(IghMyc)22Bri/J). Cohorts of mice
were monitored for lymphoma-free survival over time before generating a
Kaplan-Meier survival curve. Lymphoma was documented in every mouse
scored as a fatality in the Kaplan-Meier analysis. Mice were censored from
analysis when used for breeding or an experiment. Peripheral blood was
sampled periodically by retro-orbital eye bleeds and analyzed by the
Laboratory of Comparative Pathology at Memorial Sloan-Kettering Cancer
Center.

Analyses included complete counts of major lymphocyte

populations and viewing of blood smears by pathologists.
6.3.2 Bone marrow and cultured B-cell experiments
For bone marrow analysis, cell suspensions were flushed from femurs
and tibias, treated with erythrocyte lysis buffer (9 volumes of 150 mM
NH4Cl, 1 volume of 130 mM Tris-Cl, pH 7.65), and stained with B220-APC
(1:50, BD Pharmingen) for 20 minutes on ice to label B-cells. Cells were
fixed in 3% paraformaldehyde for 15 minutes at room temperature,
permeabilized in 2% Triton X-100/PBS for 15 minutes at room temperature,
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then assayed by TUNEL. Apoptosis was measured in proliferating B-cells
by gating large-scattering B220+ cells.
Eµ-Myc B-cells were purified from spleen preparations by magnetic
depletion of non-B-cells, as described in Chapter 3. An aliquot of cells was
saved from each preparation to verify the purity of the depleted samples, as
described in Chapter 3. Purified B-cells were cultured at a density of 106
cells/mL in B-cell medium (50% Iscove's MEM, 50% DMEM, 100 U/ml
penicillin, 100 g/ml streptomycin, 4 mM l-glutamine and 25 µM 2mercaptoethanol) in the absence of serum for 3.5 hours, prior to performing
TUNEL as described in Chapter 3.
6.4 RESULTS
6.4.1 The ΔRING mutation improved survival of the Eµ-Myc mouse
lymphoma model
Removing the RING domain rendered XIAP a worse caspase inhibitor
in embryonic cells, which suggests that the ΔRING allele is a loss-offunction. We explored the effects of this mutation on a mouse lymphoma
and leukemia model where apoptosis has an essential tumor suppression
function. By crossing the ΔRING allele onto the Eµ-Myc background and
following the survival of WT and ΔRING mice over time, we found that
ΔRING mice showed improved survival on this sensitized background
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Figure 6.1 Genetic deletion of XIAP RING prolongs life in the Eµ -Myc
lymphoma model. (A) Kaplan-Meier survival curve of WT and ΔRING
mice on the Eµ-Myc background. (B) Kaplan-Meier survival curve of WT
and XIAP-null mice on the Eµ-Myc background.
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(Figure 6.1A; p = 0.010). The median survival time for WT mice was 135
days, whereas median survival time increased to 246 days for ΔRING mice
on the Eµ-Myc genetic background. 32.0% of ΔRING mice were alive after
45 weeks, while 8.4% of WT mice survived that long; the number of WT EµMyc mice still alive was consistent with published data on the comparatively
resistant C57BL/6 strain (Sidman et al., 1988). Thus, the survival curve
demonstrates that inhibiting RING function by genetic deletion can prolong
survival of Eµ-Myc mice. Intriguingly, genetic deletion of XIAP may also
prolong survival on the Eµ-Myc background; however, the significance of
this observation awaits further monitoring of the colony (Figure 6.1B).
6.4.2 Decreased incidence of leukemia in ΔRING Eµ-Myc mice
Peripheral white blood cells progress through characteristic stages in
the course of Eµ-Myc lymphomagenesis (Sidman et al., 1993). We followed
progression through these stages by sampling blood at regular intervals from
WT and ΔRING Eµ-Myc mice.

White blood cell (WBC) counts were

comparably elevated in young mice of both genotypes (Figure 6.2A). The
WBC counts were consistent with those of mice transitioning from the first
to second stages of disease in the Eµ-Myc model (Sidman et al., 1993).
WBC counts returned to lower physiological levels by seven weeks of age in
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Figure 6.2 Lessened incidence of leukemia in Δ RING Eµ -Myc mice.
White blood cell counts in peripheral blood from mice of indicated ages.
Bars indicate mean counts.
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all mice.

The following weeks saw some WT mice begin to develop

pathological WBC counts characteristic of leukemia, whereas ΔRING mice
maintained consistently low counts over the same period (Figure 6.2B).
Large leukocytes typical of lymphoblastic leukemia were noted in peripheral
blood from all mice with pathologically elevated WBC counts. Therefore,
loss of the XIAP RING curtailed leukemia on the Eµ-Myc background.
6.4.3 ΔRING Eµ-Myc B-cells were sensitized to apoptosis in the bone
marrow
Proliferating B-cells in Eµ-Myc mice can be distinguished based on
their increased size (Langdon et al., 1986; Sidman et al., 1993).

This

population of cells co-labels with BrdU, and represents a significantly larger
percentage of the Eµ-Myc bone marrow compared to nontransgenic mice
(Langdon et al., 1986). In fact, the larger size of Eµ-Myc lymphocytes can
be used to genotype transgenic mice unambiguously (Harris et al., 1988).
We isolated bone marrow from Eµ-Myc mice and found decreased numbers
of large proliferating B-cells in the bone marrow of ΔRING transgenic mice
of different ages (Figure 6.3A). The percentages of large B-cells in the bone
marrow increased with time in mice of both genotypes, but ΔRING mice
always had fewer large cells. The fraction of TUNEL-positive, apoptotic
cells was elevated in the large B-cell population in ΔRING Eµ-Myc mice
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Figure 6.3 Decreased abundance and increased apoptosis of
proliferating B-cells in Δ RING Eµ -Myc bone marrow. Histograms
showing: (A) the percentages of small (resting) and large (proliferating)
B220+ cells in the bone marrow of age-matched Eµ-Myc mice. (B) TUNEL
in the large-scattering B220+ cell population.
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(Figure 6.3B). These findings support the notion that the ΔRING mutation
constitutes a loss-of-function allele that can promote apoptosis in vivo.
6.4.4 Loss of XIAP RING facilitated apoptosis of cultured Eµ-Myc B-cells
Apoptotic Eµ-Myc cells are rapidly cleared by phagocytes in situ
(Jacobsen et al., 1994). This observation may explain why TUNEL-positive
cells were scarce even in the proliferating population of B-cells that
undergoes high levels of Eµ-Myc-driven apoptosis in the bone marrow
(Figure 6.3B). We isolated pure populations of B-cells from the spleens of
Eµ-Myc mice to characterize apoptosis under cell culture conditions in the
absence of phagocytes. Before isolation, the major cell populations in the
spleens of WT and ΔRING Eµ-Myc mice were distributed similarly (Figure
6.4A, B) and consistent with a prior account (Langdon et al., 1986). After
purifying B-cells, the isolated cells were nearly pure populations of early Bcells (>95% B220+, CD43-, IgM-) as assessed by flow cytometry. We
deprived the purified Eµ-Myc B-cells of serum because B-cells that
misexpress Myc are strongly sensitized to apoptosis caused by growth factor
withdrawal (Cherney et al., 1994; Milner et al., 1993). B-cells isolated from

ΔRING mice showed significantly greater apoptosis after 3.5 hours of serum
deprivation in culture (Figure 6.4C; p < 0.01 by two-tailed Student’s t-test).
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Figure 6.4 Δ RING Eµ -Myc B-cells were sensitized to serum withdrawal.
(A) Compositions of WT and ΔRING Eµ-Myc spleens as assessed by flow
cytometry. (B) Distributions of B220+ cells in spleens. (C) B-cells purified
from spleens were cultured without serum for 3.5 hours before performing
TUNEL. Black bars denote mean values.
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This result is in line with the elevated apoptosis seen in freshly isolated bone
marrow, and it further supports the notion that loss of XIAP RING function
sensitizes pre-malignant B-cells to apoptosis.
6.5 DISCUSSION
XIAP

has

been

implicated

in

human

tumorigenesis

and

lymphoproliferative diseases (Nakagawa et al., 2005; Rigaud et al., 2006;
Tamm et al., 2000), and inhibiting XIAP and other IAPs with
Smac/DIABLO-derived peptides (Fulda et al., 2002) or small molecule
antagonists (Petersen et al., 2007) can reduce tumor xenografts in mice. To
our knowledge, there are no reports showing a causative role for XIAP in
tumor models. We provide evidence that loss of XIAP RING function
synergized with Eµ-Myc to enhance survival in a model of lymphoma and
leukemia. A prevailing notion holds that XIAP overexpression enhances
tumor cell survival.

Since deleting the RING rendered XIAP a worse

inhibitor of caspases, our findings with the Eµ-Myc model are consistent
with the notion that the ΔRING mutation is a loss-of-function allele.
The sensitized Eµ-Myc background was necessary to reveal that loss
of XIAP RING function has a pro-survival effect in lymphocytes. The
increased sensitivity to apoptosis when Myc is misexpressed lowers the
threshold to caspase activation, in part because of Myc-dependent activation
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of ARF (Eischen et al., 1999). Indeed, improved survival on this background
is also seen when Mdm2 expression is reduced by genetic deletion (Alt et al.,
2003).

This study also identified decreased numbers of peripheral

lymphocytes and increased spontaneous apoptosis in cells cultured without
survival factors. XIAP ΔRING did not afford as much protection as Mdm2
deficiency. This is not surprising perhaps because specific p53-dependent
apoptosis underlies the death of Eµ-Myc cells (Eischen et al., 1999; Schmitt
et al., 1999). Presumably, loss of anti-apoptotic BCL-2 genes would also
stimulate apoptosis and improve survival on this background.

To our

knowledge, this experiment has not been done yet. This would probably
require adoptive transfer of bone marrow or lymphoma cells because
knockouts of anti-apoptotic BCL-2 genes result in lethality.
The molecular basis for our phenotype is unclear. The mechanism
may arise from decreased caspase ubiquitination during p53-mediated death
of Eµ-Myc B-cells. This hypothesis is testable, but we were unable to obtain
enough input material from our existing Eµ-Myc colony to investigate
caspase-3 ubiquitination (the caspase-3 immunoprecipitation described in
Chapter 4 required 1 mg of input lysate). Enhanced sensitivity to deathreceptor apoptosis, seen in ΔRING MEFs, may offer some clues into the
mechanism of prolonged survival. Myc expression sensitizes cells to TRAIL
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(Ricci et al., 2007), and loss of the TRAIL (Finnberg et al., 2008) or Fas
(Zornig et al., 1995) receptors worsens prognosis on a Myc background.
Unfortunately, we were unable to test this hypothesis because treatment with
TRAIL, Fas, or TNF-α (all with and without cycloheximide) did not raise
the levels of apoptosis beyond background levels, even when serum was
removed.

Others have noted that Eµ-Myc cells do not die readily in

response to these treatments as well (Finnberg et al., 2008). It remains
unclear how death receptors modulate the phenotype of Eµ-Myc mice.
It is also possible that the XIAP RING has in indirect role in this
context, through RING-dependent interactions with cIAP1.

cIAP1 was

recently identified as a ubiquitin-ligase that targets Mad1, an inhibitor of
Myc, for degradation, thereby enhancing proliferation and colony formation
(Xu et al., 2007).

This idea is speculative, but perhaps RING-RING

interactions normally promote the formation of a XIAP/cIAP1 heterodimer
that enhances cIAP1-dependent ubiquitination of Mad1. The absence of
XIAP RING could then inhibit cIAP1-mediated turnover of Mad1 and
dampen Myc-dependent proliferative signals. This hypothesis is testable by
immunoblotting.
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7 CONCLUDING DISCUSSION AND IMPLICATIONS
FOR FUTURE RESEARCH
7.1 Perspective
Previous efforts to study the regulation of apoptosis by XIAP have
largely focused on how BIR domains bind and inhibit caspases, often by
relying on overexpression in cancer cell lines and on the biochemical and
structural analyses of isolated domains (Hunter et al., 2007).

These

approaches have offered valuable insights into the molecular mechanisms by
which XIAP may regulate caspases, and they also guided the design of
small-molecule therapeutics that disrupt BIR/caspase complexes to promote
apoptosis in tumors (Carter et al., 2005; Petersen et al., 2007; Varfolomeev
et al., 2007; Vince et al., 2007). The results from this study emphasize the
importance of the RING domain, which bestows E3-ubiqutin ligase activity
on XIAP, for the negative regulation of caspases, cell death and tumor
suppression by XIAP in vivo. The RING may be a promising target for
therapeutic intervention in some cancers because genetic removal of this
domain limited the abundance of proliferating, pre-malignant B cells and
prolonged survival in a mouse model of lymphoma, without adversely
affecting lymphoid cells or causing any other overt negative consequences in
control mice. Since we also observed elevated spontaneous apoptosis in
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transformed ΔRING MEFs, these observations may extend to other
transformed cells.
7.2 Comparisons between DIAP1 and XIAP RING function
Studies on the DIAP1 RING in Drosophila show that cells can use
RING ubiquitin-ligase activity to exert both pro- and anti-apoptotic effects.
An antiapoptotic role for DIAP1 RING function in healthy cells was
revealed using mutant animals: point mutations that inactivate key structural
residues in the DIAP1 RING are lethal as advanced embryos (Lisi et al.,
2000; Wilson et al., 2002), and a ΔRING truncation causes virtually every
embryonic cell to die by apoptosis (Goyal et al., 2000). Point mutations that
inactivate RING ubiquitin-ligase function do not preclude DIAP1 from
binding

the

initiator

caspase

DRONC,

but

they

polyubiquitination of Dronc (Wilson et al., 2002).

do

prevent

The failure to

ubiquitinate DRONC has catastrophic consequences in tissues like the wing
imaginal disc: DRONC immunostaining increases dramatically, probably
through enhanced stability of the protein; effector caspases are activated;
and cells die by apoptosis (Ryoo et al., 2002; Ryoo et al., 2004). These
experiments describe an essential anti-apoptotic function for the DIAP1
RING in the developing embryo by ubiquitinating DRONC and preventing it
from triggering apoptosis in cells that should normally live.
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An opposing pro-apoptotic function for the RING has emerged from
studies on the DIAP1 antagonist Reaper, which is transcribed only in dying
cells. Expression of Reaper depletes DIAP1 through RING-dependent
autoubiquitination, and this leads to apoptosis (Ryoo et al., 2002). The case
for a pro-apoptotic DIAP1 RING function is further strengthened by genetic
interaction studies that show a requirement for Ubcd1, the cognate E2
ubiquitin conjugating enzyme for DIAP1, in Reaper-dependent apoptosis
(Ryoo et al., 2002). Collectively, these experiments imply that the outcome
and targets of RING-dependent ubiquitination depends on the state of the
cell: healthy cells can employ the RING to keep caspases in check, and
dying cells engage it to permanently lower the threshold against cell death.
How

RING

ubiquitin-ligase

activity

regulates

mammalian cells was largely unknown until now.

apoptosis

in

There are certain

parallels between Drosophila and mammalian IAP RING functions,
especially with regard to ubiquitination substrates. The first links between
the ubiquitin system and IAP RING function were described in mouse
thymocytes (Yang et al., 2000). RING-dependent autoubiquitination and
downregulation of XIAP and cIAP1 was proposed as a mechanism
explaining why the proteasome is required for thymocyte apoptosis (Yang
and Li, 2000). Depletion of IAPs through the ubiquitin system does not
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seem to be a universal phenomenon, however, and some cells still die when
IAPs are abundantly expressed (ES cells, for example). In thymocytes,
increasing the abundance of XIAP by removing the RING did not affect
apoptosis, however, so it remains unclear why IAPs are degraded so rapidly
by the proteasome in these cells.

It is possible that the heightened

importance of the ubiquitin system in thymocytes enhances the natural
tendency of RING domain IAPs to degrade themselves (Silke et al., 2005).
The degradation of other IAPs may be sufficient to lower the inhibitory
threshold against cell death in spite of XIAP persistence. Moreover, the
factor(s) that actively promotes IAP turnover during thymocyte remain
elusive.
Specific inhibition of XIAP is required for cytochrome c-mediated
apoptosis in mouse sympathetic neurons, and this occurs by posttranslational downregulation in dying cells (Potts et al., 2003). Primary
neuronal cultures from XIAP-null mice die in response to cytochrome c
injection alone, while WT cells are resistant. Remarkably, cultured ΔRING
neurons are as sensitive to cytochrome c injection as knockout cells (M.
Deshmukh, personal communication). This strengthens the notion that the
XIAP RING deletion is a loss-of-function allele, while casting further doubt
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on the role of ubiquitin-mediated turnover in promoting apoptosis in primary
cells.
In addition to autoubiquitination, XIAP can function as a ubiquitin
ligase for most of its binding partners, at least in overexpression and in vitro
assays.

The effects can be both pro- and anti-apoptotic.

Ectopically

expressed XIAP can promote polyubiquitination of caspases-3, -7 and -9,
and this effect can have anti-apoptotic consequences by antagonizing
caspase function (Creagh et al., 2004; Morizane et al., 2005; Suzuki et al.,
2001). We did not observe appreciable increases in the expression levels of
these caspases, however. The XIAP RING functions anti-apoptotically in
primary hepatocytes treated with TGF-β by targeting TAK1 for degradation
and thereby attenuating apoptosis through the JNK pathway (Kaur et al.,
2005). We did not see any altered expression of TAK1 in MEFs during
TNF-α/CHX apoptosis, and it will be worthwhile investigating the
consequences of the RING mutation in hepatocyte cultures especially since
cIAP1 overexpression contributes to hepatocellular carcinoma (Zender et al.,
2006).

Anti-apoptotic functions for the RING were inferred from the

observation that XIAP can polyubiquitinate its antagonist ARTS and target it
for degradation (Lotan et al., 2005), though it is unclear if Smac/DIABLO is
a ubiquitination substrate as well (Creagh et al., 2004; MacFarlane et al.,
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2002). XIAP also acts independently of cell death pathways to influence
intracellular copper levels through ubiquitin-dependent regulation of the
copper regulatory protein MURR1, and XIAP-null fibroblasts show modestly
elevated MURR1 protein expression (Burstein et al., 2004).
Since the RING can exert pro- and anti-apoptotic effects, we
engineered a ΔRING allele to genetically investigate the relative
contributions and outcomes of RING activity in primary cells and in vivo.
Inactivation of the mouse XIAP RING by gene targeting revealed parallels
with fruit fly DIAP1 RING function and differences as well. While DIAP1
RING mutants die as advanced embryos, ΔRING mice are viable on mixed
and congenic C57BL/6 backgrounds. This may reflect different regulatory
strategies utilized by Drosophila and mice. Drosophila seems to rely on
DIAP1 as a central control point in controlling apoptosis: RING-mediated
suppression of DRONC as a key regulatory step to prevent accidental
caspase activation (Wilson et al., 2002), and IAP antagonists are absolutely
required for apoptosis (White et al., 1994). Many mammalian cells seem to
control apoptosis initiation more stringently upstream of mitochondria
(Lindsten et al., 2000; Wei et al., 2001) while particular IAPs (XIAP, cIAP1,
cIAP2) and IAP antagonists (Smac/DIABLO, Omi/HtrA2, ARTS) are
dispensable individually for regulating apoptosis during development. The
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lack of strong phenotypes in mice deficient for individual negative
regulators is perhaps not surprising, as cell death pathways are almost
certainly redundant in comparatively long-lived animals. Furthermore, it is
very likely that there are additional negative regulators of apoptosis apart
from known caspase inhibitors like IAPs. This is an area of research that
merits further investigation.
Nonetheless, we have shown that XIAP RING function influences
caspase functions in embryonic cells.

Caspase-3 enzyme activity was

elevated in ΔRING cells in response to diverse apoptotic stimuli and
irradiated MEFs were defective in caspase subunit ubiquitination. Unlike
DIAP1 RING mutant cells, caspase subunit abundance was not dramatically
altered in apoptotic ΔRING cells, which leaves open the possibility that
polyubiquitination may not lead to degradation of caspases. In principle the
ubiquitination of active caspase-3 by a functional XIAP RING could impair
the enzymatic activity of a caspase or its ability to form functional dimers,
although ΔRING cells could tolerate higher caspase activity without
increased death when cells were killed through the mitochondrial pathway of
apoptosis. WT XIAP was not cleaved much during thymocyte apoptosis,
while cleavage products were detected during TNF-α-dependent apoptosis in
MEFs. The presence or absence of a polyubiquitin chain may determine if
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XIAP can be cleaved by caspases, because XIAP was cleaved by caspases
only in situations when it was not very labile.
7.3 IAPs in death receptor signaling
IAPs have diverse regulatory roles in death receptor signaling
pathways that have become known recently (Li et al., 2004; Varfolomeev et
al., 2007; Vince et al., 2007). Much of this evidence comes from studies
with IAP antagonist compounds that can liberate caspase-3 from XIAP and
trigger cIAP1/2 autoubiquitination and degradation.

IAP antagonists

synergize with apoptotic stimuli to induce apoptosis in most human cancer
cell lines studied so far, and some cell lines are killed by the compound
alone (Petersen et al., 2007).

Our findings may offer some important

mechanistic insights into how IAP antagonists induce apoptosis. cIAP1/2
are degraded within minutes after IAP antagonist treatment, while XIAP
remains relatively stable (Varfolomeev et al., 2007; Vince et al., 2007). The
authors describe a mechanism where TNF-α is transcribed through a NF-κBdependent mechanism (normally inhibited by cIAP1/2), and induces
apoptosis through autocrine signaling.

While IAP antagonists do not

strongly promote XIAP degradation, they do bind XIAP very tightly and
prevent it from binding caspase-3 (Li et al., 2004; Vucic and Fairbrother,
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2007). This effect may functionally substitute for genetic deletion of XIAP,
which we have shown to sensitize cells to TNF-α-dependent apoptosis.
The mechanism for TNF-α and TRAIL sensitivity remains elusive.
RING ubiquitin-ligases usually function to regulate the abundance of their
binding partners, but the differential sensitivity between WT and ΔRING
cells was not obvious from the protein expression levels of key components
in the TNF effector pathways. A proteomics effort may be useful to identify
proteins that are upregulated in mutant cells during the earliest stages of
TNF-α apoptosis signaling. This method may identify misregulated factors,
normally kept in lower abundance by XIAP RING-mediated turnover, which
may underlie sensitization.

Alternatively, the mechanism may be

independent from ubiquitination, and may instead arise instead if factors
involved in death receptor signaling were mislocalized in the cell. In this
regard, a comprehensive examination of the subcellular localizations of key
signaling components may offer some insights.
The sensitivity to death receptor apoptosis was not common to all
ΔRING cell types, however: hepatocellular apoptosis occurred normally in
vivo following intravenous administration of agonistic Fas antibody, or
TNF-α together with the liver-selective transcriptional inhibitor GalN. A
key difference between death receptor apoptosis in MEFs and hepatocytes is

167

the obligate requirement for mitochondrial factors in hepatocyte apoptosis
(Yin et al., 1999), and it is possible that one of these proteins modulates the
effect of the ΔRING mutation. This may also account for the otherwise
normal cell death that occurs in embryonic cells killed by stimuli that act
through the mitochondrial pathway of apoptosis.
7.4 Implications for XIAP in tumor suppression and disease
Although ΔRING mice appeared as healthy as WT littermates, we
found an anti-apoptotic role for RING function after crossing mutant mice
onto the Eµ-Myc transgenic background. The importance of apoptosis in
modulating cancer progression in Eµ-Myc mice is evident from animals
carrying mutations in cell death genes (Schmitt et al., 2002; Strasser et al.,
1990).

We found small but reproducible increases in apoptosis in the

population of proliferating, pre-malignant ΔRING B-cells in the bone
marrow and in culture, and a general decrease in their relative abundance.
This genetic evidence supports the long-standing notion that XIAP
antagonism can lead to the death of cancer cells (Hunter et al., 2007).
In principal, it is possible to mimic the effects of the XIAP ΔRING
mutation by using a small-molecule inhibitor of the RING (Sun, 2003). Our
results suggest that such an inhibitor may have therapeutic benefits in
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lymphoma and leukemia, and possibly other malignancies. A screen for
XIAP RING inhibitors could use methods developed for identifying smallmolecule antagonists of the RING domain of Hdm2, the ubiquitin-ligase that
suppresses p53 expression in human cells (Davydov et al., 2004; Murray et
al., 2007).

Hdm2 RING antagonists repress autoubiquitination in vitro,

increase the abundance of p53 in cells, and can induce apoptosis (Yang et
al., 2005). The inhibitors identified to date are neither very specific nor
potent; however, the field is in its infancy, and optimized techniques will
undoubtedly yield better inhibitors. Another concern about using an XIAP
RING inhibitor is raised by the observation that heritable mutations in XIAP
underlie a human X-linked lymphoproliferative syndrome, characterized by
increased TRAIL and Fas death receptor apoptosis and depletion of natural
killer T-lymphocytes (Rigaud et al., 2006). XIAP RING inhibitors may
have a therapeutic window similar to bortezomib, a proteasome inhibitor
currently in use as a treatment for multiple myeloma; multiple myeloma
cells can be killed by apoptosis even by a modest decrease in proteasome
activity (Chauhan et al., 2008).
XIAP deficiency does not significantly alter tumor development in a
mouse model of prostate cancer (Hwang et al., 2008). This finding suggests
that XIAP may not play a key role in the development of all tumors.
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However, emerging data implicate IAPs in regulating hematopoietic
malignancies, melanoma and hepatocellular carcinoma, among other
cancers. The results presented here complement recent findings that genetic
deletion of the Sept4 locus, which encodes the IAP antagonist ARTS,
dramatically accelerates lymphomagenesis in the Eµ-Myc model (M. GarciaFernandez, unpublished data). The findings using mouse knockouts are
entirely consistent with the hypothesis that XIAP has an anti-apoptotic role
in lymphoid malignancy that can be inhibited by antagonists like ARTS. It
is very likely that more roles for IAPs will be uncovered in different
malignancies.

For example, melanocytes upregulate ML-IAP during

melanoma development and small-molecule IAP antagonists have entered
clinical trials for treatment of this disease.
Complementary roles for IAPs and IAP antagonists are observed in
liver cancer as well.

cIAP1 gain-of-function has a causative role in

hepatocellular carcinoma (Zender et al., 2006), while loss of the ARTS IAP
antagonist

dramatically

predisposes

mice

to

chemically

induced

carcinogenesis in the liver (C. Pham, unpublished data). It is unclear if
XIAP is the principal ARTS target in the liver, but it will be worthwhile
investigating the roles of XIAP loss-of-function alleles, such as ΔRING, in
mouse models of liver cancer.
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The dramatic sensitivity to TNF-α and TRAIL apoptosis seen in

ΔRING embryonic fibroblasts may also apply to other tissues and function in
the response to inflammation or infection. Although ΔRING hepatocytes
activated caspase-3 with normal kinetics in response to TNF-α
administration, other mouse models of infection or endotoxic shock may
reveal sensitivity to apoptotic cytokine responses. TNF-α has a causative
role in inflammatory diseases like rheumatoid arthritis, where the
inflammatory

cytokines

originate

from

TNF-α-stimulated

synovial

fibroblasts (Fox, 2000). Perhaps the local inhibition of XIAP function in
synovial joints by IAP antagonists could terminate the TNF-α signal by
inducing apoptosis in fibroblasts, and subvert the long-term inflammatory
effects. It will also be worthwhile investigating apoptosis in diverse postmitotic cell types, since XIAP-deficiency or the ΔRING mutation predispose
sympathetic neurons to apoptosis under culture conditions. Collectively, our
data demonstrate that XIAP, and RING function in particular, plays a far
greater role in regulating apoptosis in vivo than was previously recognized.
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8 APPENDICES
8.1 Antibodies used for immunoblotting
Antibody

Manufacturer / order #

Dilution

Actin
Bcl-XL
Caspase-3 (p17)

Sigma AC-15
Cell Signaling 2764
Cell Signaling 9661

1:20000
1:1000
1:1000

Caspase-3 (p32/17)

Cell Signaling 8G10

1:1000

Caspase-3 (p32/p12) Gift from Joe Rodriguez 1:3000
Caspase-7
Caspase-8

Gift from Joe Rodriguez 1:1000
Cell Signaling 4927
1:1000

Caspase-8 (cleaved)

Cell Signaling 18C8

1:1000

Caspase-9

Cell Signaling 9504

1:1000

c-FLIP

Cell Signaling 3210

1:1000

cIAP1

R&D AF818

1:2000

FADD

Santa Cruz M-19

1:500

NIK
PARP
Phospho-JNK

Santa Cruz H-248
BD clone C-2-10
Cell Signaling 9251

1:500
1:2000
1:1000

RIP1
Smac/DIABLO
Survivin

Cell Signaling 4926
BD monoclonal #56
R&D AF886

1:1000
1:1000
1:2000

TAK1
TNF-R1
Total JNK
TRAF2
Ubiquitin
XIAP

Cell Signaling 4505
Santa Cruz H-5
Santa Cruz sc-571
Cell Signaling 4712
Sigma U5379
BD monoclonal #28

1:1000
1:500
1:2000
1:1000
1:500
1:1000
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8.2 The curious case of the XIAP H466A/Δ RING mouse
The XIAP ΔRING mouse was our second attempt to make a RINGmutant allele. Our initial approach was to knock-in a single amino acid
substitution (H466A) in the RING, thereby removing a residue essential for
RING function.

We also included the option to remove the domain

altogether by flanking the sixth exon (encoding the RING) with loxP sites
for excision by the Cre recombinase. We positioned loxP sites in the final
intron and 3’ UTR, so that Cre would excise the final exon and the splicing
machinery would retain the final intron in the spliced mRNA (Figure A).
Excising exon 6 would generate a truncated protein because of a fortuitous
in-frame stop codon in the former final intron. All steps of gene targeting
were carried out successfully and chimeric mice transmitted the mutant
allele through the germline. We did some preliminary experiments with ES
cells similar to those described above. We were surprised to find that the
XIAP H466A protein was virtually undetectable in ES cells after transient
FLPe expression to delete the Neo box (Figure B). We also deleted the final
exon by expressing Cre recombinase using a self-excising, “hit and run” Cre
recombinase retrovirus.

Deleting the final exon did in fact generate a

truncated protein, but this too was expressed at nearly undetectable levels.
Moreover, low XIAP H466A expression was seen in other cells (Figure C).

173

We obtained identical results after lysing cells in 8 M urea before
immunoblotting. Furthermore, XIAP H466A expression was insensitive to
proteasome or lysosome inhibitors.

We found that the mRNA was

expressed normally in MEFs after doing a Northern blot (Figure D). We
concluded that the loxP site in the 3’ UTR was inhibiting translation of the
XIAP H466A message, perhaps by interrupting an element necessary for
translation or by creating a micro-RNA binding site by accident.
Furthermore, the XIAP H466A knockdown phenocopies a complete XIAPnull in TNF-α-dependent apoptosis (Figure E).
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Appendix Figure (A) Gene targeting strategy. Immunoblot of XIAP
expression in H466A and ΔRING ES cells (B) and thymocytes/splenocytes
(C). (D) MEF Northern blots. (E) TUNEL in MEFs after 8h TNF-α/CHX.
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